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ABSTRACT 
Background 
Oesophageal cancer is highly fatal and treatment with curative intent is beset with many side 
effects. Treatment options are (1) chemoradiotherapy, (2) chemotherapy with or without the 
addition of radiotherapy followed by surgery or (3) surgery alone. The aims of this thesis are 
to evaluate outcome and side effects from neoadjuvant treatment followed by surgery and 
from definitive chemoradiotherapy in combination with cetuximab. 
 
Patients and methods 
NeoRes I is a prospective, randomised, multicentre trial reported in Papers I and II. Patients 
with resectable oesophageal cancer were randomly allocated to receive three 21-days cycles 
of cisplatin and fluorouracil with or without the addition of radiotherapy to 40 Gy followed 
by oesophageal resection. 
 
In Paper III the effects on cardiac exercise test and on pulmonary function after neoadjuvant 
treatment and 1-2 years after surgery were investigated in a cohort of 97 patients included in 
the NeoRes I trial.  
 
LERFOX-C is a prospective, non-randomised, multicentre trial reported in Paper IV. Eligible 
patients had localized oesophageal cancer not suitable for surgery. Treatment consisted of 
radiotherapy to 50 Gy concurrent with weekly cetuximab and three 21-days cycles of 
oxaliplatin and fluorouracil. 
 
Results 
In papers I and II, 181 patients were included. All three chemotherapy cycles were delivered 
to 73% of the patients allocated to chemoradiotherapy and to 86% of those allocated to 
chemotherapy. 87% of those allocated to chemoradiotherapy received at least 30 Gy. 87% in 
the chemoradiotherapy group and 86% in the chemotherapy group underwent tumour 
resection. Tumour response was better among those allocated to chemoradiotherapy with 
fewer metastatic lymph nodes at resection, a higher rate of radical resection and a higher rate 
of complete histopathological response (28% versus 9%), but 5-year overall survival was 
similar (42% versus 40%). 
 
In Paper III we found a slight decrease in vital capacity and forced expiratory volume in 1 
second after neoadjuvant treatment, and a more profound decrease 1-2 years after surgery. 
Maximum exercise capacity decreased after neoadjuvant treatment and persisted and 1-2 
years after surgery. We did not find any significant differences between the treatment groups.  
 
In Paper IV, 51 patients were eligible for survival analysis and 46 were eligible for toxicity 
and recurrence analysis. Full radiotherapy dose was delivered to 80%, 75% received all three 
cycles of chemotherapy and 73% received four or more doses of cetuximab. Within six 
months from the end of treatment, six patients died from complications from fistulas between 
the oesophagus and aorta or airways. The estimated loco-regional progression-free survival at 
one year was 47%. Overall survival at three years was 29%. 
 
Conclusions 
The addition of radiotherapy to neoadjuvant chemotherapy increases tumour response in 
patients with localized, resectable oesophageal cancer without affecting patterns of recurrence 
or survival. Multimodality treatment causes short-term and long-lasting impairment in 
pulmonary function and exercise capacity. Oxaliplatin and fluorouracil given concurrent with 
radiotherapy and cetuximab is well tolerated and has a curative potential in the treatment of 
localized oesophageal cancer. However, results from recent phase III trials do not support the 
addition of cetuximab and cannot be recommended as standard of care.  
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1 INTRODUCTION 
1.1 EPIDEMIOLOGY 
Oesophageal cancer is the twelfth most common cancer worldwide. The prognosis is 
gloomy visualized by the fact that it is the seventh leading cause of cancer related death1. It 
is a rare disease among the young, and it typically affects people in the seventh and eights 
decade of life2. 
The vast majority of oesophageal cancers are squamous cell carcinoma or adenocarcinoma. 
They do not only differ histologically but also with respect to aetiology, geographic 
distribution and anatomical location.  
Adenocarcinoma derives from the glandular cells and typically arises in the lower third of the 
oesophagus. Squamous cell carcinomas are in most cases located in the upper two thirds of 
the oesophagus3.  
The geographic distribution is uneven. A high incidence of squamous cell carcinoma is found 
in South-East and Central Asia and in Southern and Eastern Africa. (Figures 1 and 2). In the 
western world, oesophageal cancer is still a rare disease, although the incidence of 
adenocarcinoma is rapidly increasing (Figure 3) and is now the predominant type4,5. The 
incidence of oesophageal cancer in Sweden 2014 was 2.6 per 100 000 women and 8.0 per 
100 000 men6. 
 
Figure 1 Age-standardized incidence rate (ASR) per 100 000 of  
(A) oesophageal carcinoma and (B) squamous cell carcinoma in women 
 
 
  
A 
B 
Used with permission 
Melina Arnold et al. Gut 2015;64:381-387 
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Figure 2 Age-standardised incidence rate (ASR) per 100 000 of  
(A) oesophageal adenocarcinoma and (B) squamous cell carcinoma in men.  
 
 
 
 
 
Figure 3 Incidence of adenocarcinoma of the oesophagus and the gastric cardia from 
Surveillance Epidemiology and End Results (SEER) 9 database from the National Cancer 
Institute in the USA. 
 
  
Used with permission 
Dubecz A et al. Journal of Gastrointestinal Surgery 2014; 18(1): 124-9. 
A 
B 
Used with permission 
Melina Arnold et al. Gut 2015;64:381-387 
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1.2 RISK FACTORS 
1.2.1 Smoking 
Tobacco smoking multiplies the risk of developing squamous cell carcinoma in the 
oesophagus. There is also a link between smoking and adenocarcinoma, even though the 
association is weaker than for squamous cell carcinoma. Several studies have been conducted 
to investigate the relationship between tobacco use and the development of oesophageal 
cancer and there seems to be a dose-dependent association between tobacco smoking and the 
evolution of oesophageal cancer7. It has also been shown that in the development of 
squamous cell carcinoma, tobacco smoking acts synergistically with alcohol consumption8. 
1.2.2 Alcohol 
Alcohol intake is a major risk factor for the development of squamous cell carcinoma in the 
oesophagus and it seems to be due to the metabolite of ethanol, acetaldehyde, that interferes 
with DNA synthesis and repair9. This is also supported by the fact that Asians, who have a 
deficiency in aldehyde dehydrogenase which causes an accumulation of acetaldehyde, have 
an increased risk of developing the disease10. Similar to tobacco smoking, there seems to be a 
dose-response relationship between alcohol intake and the development of squamous cell 
carcinoma of the oesophagus11. However, there does not seem to be any relation between the 
development of adenocarcinoma and alcohol consumption7.  
1.2.3 Gastro-oesophageal reflux and obesity 
Gastro-oesophageal reflux disease is a major risk factor for developing adenocarcinoma in 
the oesophagus12. Obesity increases the risk of reflux, but even in the absence of reflux 
obesity is a risk factor for oesophageal cancer13. 
1.2.4 Barrett´s oesophagus 
The squamous cells of the oesophagus can be replaced by metaplastic columnar epithelium as 
a consequence of chronic exposure to gastric acid and bile. This so-called Barrett´s 
metaplasia gives no symptoms and is commonly discovered at endoscopic examination of 
patients with gastro-oesophageal reflux. Patients with Barrett´s oesophagus have an increased 
risk of developing adenocarcinoma in the oesophagus. In a high-quality meta-analysis 
patients with Barrett´s oesophagus have been estimated to have an annual risk of developing 
high-grade dysplasia or adenocarcinoma of approximately 0.77%14. 
 
1.3 CLINICAL PRESENTATION 
Dysphagia is the most common symptom of oesophageal cancer. In a survey of patients with 
oesophageal cancer in North-America as many as 74% reported dysphagia at diagnosis. 
Odynophagia were present in 17% and 57% had experienced weight loss. Heartburn was 
present in 21%15. Even though symptoms from gastro-oesophageal reflux are common 
among patients with oesophageal cancer, it is also common in the general population where 
the vast majority does not suffer from oesophageal cancer. In a population-based study of 
mainly white North-Americans, 20% suffered at least on a weekly basis of heartburn and/or 
acid regurgitation16. 
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1.4 DIAGNOSIS 
Upper endoscopy in general clinical practice is a reliable method to detect oesophageal 
cancer with a sensitivity as high as 94%17. For staging purposes, it is essential to detect lymph 
nodes and distant metastases. Computed tomography (CT) is easily accessible in most 
diagnostic centres, but has its limitations in detecting non-enlarged metastatic lymph nodes, 
differencing between benign and metastatic enlarged lymph nodes and detecting minor 
distant metastases. Endoscopic ultrasound has a higher detection rate of regional metastatic 
lymph nodes18, but is highly dependent on the skills of the examiner19. Fluorodeoxyglucose 
(FDG) positron emission tomography (PET) can measure metabolic activity in the body. 
When combined with a CT, three-dimensional images can be created and the sensitivity and 
specificity for detecting distant metastases is better than for CT alone20. 
1.5 STAGING AND PROGNOSIS  
Oesophageal cancer is classified in the American Joint Committee on Cancer Tumor-Nodes-
Metastasis (TNM) staging system and the latest edition (8th edition) was published in 2016. 
The classification takes into account the size and invasion of adjacent structures of the 
primary tumour, the amount and location of lymph node-metastases, the prevalence of distant 
metastases and histologic grading. In the latest edition there are different grading systems for 
clinical staging (cTNM), pathologic staging (pTNM) and after neoadjuvant treatment 
(ypTNM). The prognosis is highly dependent on the TNM staging21-23 as illustrated by Figure 
4. 
Figure 4 Survival by clinical T category. Kaplan–Meier estimates accompanied by vertical 
bars representing 68% confidence limits, equivalent to ±1 standard error.
 
 
Used with permission 
Rice TW et al. Diseases of the Esophagus 2016;29(7):707-714 
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The overall survival in patients diagnosed with oesophageal cancer is poor, and the 5-year 
survival rate among those registered in the SEER database in the United States between the 
years 2001-2009 was 22 %. The poor diagnosis is partly reflected by the fact that as many as 
37% have distant metastases at the time of diagnosis.24 
It is generally accepted that complete tumour regression in the resected specimen after 
neoadjuvant treatment is a major prognostic factor for patients with oesophageal carcinoma25. 
When there is residual carcinoma, there are several different grading systems for assessing 
the response of neoadjuvant therapy and thereby predicting outcome. Some of the grading 
systems exclusively focus on response at the primary site, and some incorporate both nodal 
and primary site response. The most commonly used grading system in oesophageal cancer is 
the five-graded scale suggested by Mandard in 1994, which focuses on response in the 
primary site26,27. Chirieac and co-workers modified the Mandard scale to a simpler four-
graded scale (Figure 5), similar to the one used in the evaluation of gastric cancer by Becker 
and co-workers 25,28. Chirieac found an association between survival and histopathologic 
grading after neoadjuvant chemoradiotherapy in 235 patients with adenocarcinoma or 
squamous cell carcinoma in the oesophagus (Figure 6). The scale developed by Chirieac was 
later used when analysing the specimens in the CROSS trial29 and was also used in the 
NeoRes I trial. 
Figure 5 Histopathologic grading of the primary tumour after neoadjuvant treatment as 
suggested by Chirieac 
 
  
(B) 1–10% residual carcinoma, characterized by rare 
individual carcinoma cells present in fibrotic tissue at the 
primary site. 
(A) No residual carcinoma, characterized by microscopic 
evidence of radiation‐induced tissue injury, regenerative 
changes, and fibrosis extending through the layers of the 
oesophageal wall. There is no histologically identifiable 
residual carcinoma. 
(C) 11–50% residual carcinoma, characterized by 
microscopic foci of carcinoma cells present at the primary 
site. 
(D) Greater than 50% residual carcinoma, characterized 
by substantial carcinoma remaining at the primary site. 
Used with permission by John Wiley & Sons, Inc.  
Chirieac LR et al. Cancer. 2005;103(7):1347-1355. 
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Figure 6 Kaplan–Meier estimates of overall survival among patients with carcinoma of the 
oesophagus and oesophagogastric junction treated with preoperative neoadjuvant 
chemoradiation. Grading of residual carcinoma as suggested by Chirieac. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Used with permission by John Wiley & Sons, Inc.  
Chirieac LR et al. Cancer. 2005;103(7):1347-1355. 
 
2 TREATMENT 
The choice of treatment for patients with oesophageal cancer depends on a variety of factors 
such as stage of the disease, location of the tumour, comorbidities and age of the patient. 
When the tumour has not spread beyond regional lymph nodes it is a potentially curable 
disease. But, often patients present with advanced (metastatic) disease and cure is out of 
reach. Curative treatment consists of surgery alone, chemoradiotherapy or a combination of 
surgery and chemotherapy with or without the addition of radiotherapy. 
2.1 CURATIVE TREATMENT 
2.1.1 Surgery 
Surgery can be performed in different ways when resecting oesophageal cancer. The two 
stage thoraco-abdominal approach (Ivor Lewis) is the most frequently used for tumours in the 
lower third of the oesophagus. The three-stage oesophagectomy (McKeown) where there is 
also a cervical incision is more regularly used in the upper third of the oesophagus. In three-
stage oesophagectomy a cervical lymph node dissection (=three-field lymphadenectomy) 
may or may not be added. Three-field lymphadenectomy is often practiced in Asia for mid 
and upper third cancers, while practiced much more restrictively in Western countries. 
Results from ongoing randomised trials in China and India comparing two-field and three-
field lymphadenectomy are awaited. A gastric tube, constructed out of the major curvature of 
the stomach with vascular supply mainly from the right gastroepiploic vessels, is used to 
substitute the oesophagus and the anastomosis is either intrathoracic or cervical. 
A less traumatic procedure is the trans-hiatal approach, which can be used for tumours in the 
lower half of the oesophagus. As the lymph node dissection then is performed from the 
abdomen it will not be as radical in the mid and upper part of the mediastinum as it will be 
with the transthoracic approach.  
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A randomised study comparing the trans-hiatal and the thoracic-abdominal approach has not 
shown any survival advantage for either of the two techniques. However, in a sub-group 
analysis a survival benefit in favour of the thoraco-abdominal approach was shown for those 
with a limited number of pathological lymph nodes30. In clinical practice, nodal staging 
before surgery is often not consistent with pathological staging. Therefore, the thoraco-
abdominal technique is often advocated if the patient is fit enough31.  
In recent years minimal invasive techniques have been introduced. With this procedure 
endoscopic methods are used instead of thoracotomy and laparotomy. The TIME-trial32 
shows short-term advantages in terms of reduced morbidity and enhanced recovery after 
surgery without jeopardizing the R0-resection rate and the number of lymph nodes retrieved.  
The findings are supported by the MIRO-trial presented at ESMO in 201733. 
2.1.2 Chemotherapy 
The role of chemotherapy in the curative treatment of oesophageal cancer is to eliminate 
micrometastases and downsize the primary tumour. When given concurrent with radiotherapy 
it enhances injury to the deoxyribonucleic acid (DNA) or prevents its repair with the aim to 
overcome radioresistance of the tumour34. Chemotherapy cannot as a single modality cure 
oesophageal cancer.  
The use of neoadjuvant chemotherapy and chemoradiotherapy developed in the 1970s34. The 
agents chosen were drugs that had been shown to be successful in other tumours. The use of 
cisplatin-based regimens in a pre-operative setting was first reported from Memorial Sloan-
Kettering35 and the use of cisplatin is still considered the gold standard in the neoadjuvant 
treatment of oesophageal cancer. The mode of action of cisplatin is cross-linking with the 
purine bases in the DNA and thereby causing DNA-damage and interference with DNA 
repair mechanisms, which results in apoptosis36. 
Cisplatin was at first combined with bleomycin that was later replaced by fluorouracil37 
which have fewer pulmonary side effects. Fluorouracil is an antimetabolite which inhibits the 
action of thymidylate synthase and the replication and repair of DNA is thereby hampered. 
Fluorouracil is also incorporated into RNA which results in impaired function of RNA38 and 
the antitumoural effect is enhanced. Other drugs have been combined with cisplatin, but 
fluorouracil is probably the most well-documented radio-sensitizer34 and the combination of 
fluorouracil and cisplatin is well established in the treatment of oesophageal cancer. The US 
collaborative group, CALGB, showed that the addition of neoadjuvant cisplatin, fluorouracil 
and radiotherapy to surgery improved 5-year survival from 16 to 39% compared to surgery 
alone39 and Ychou et al. found that peri-operative cisplatin- fluorouracil improved 5-year 
survival for patients with gastro-oesophageal adenocarcinoma compared to surgery alone 
from 24 to 38%40. A newer platinum analogue, oxaliplatin, appears to be as effective as 
cisplatin in the treatment of oesophageal cancer41,42, but has a shorter infusion time and fewer 
ototoxic and renal side effects. Like cisplatin, oxaliplatin reacts with DNA bases which 
results in DNA cross-links43.  
A more recently developed group of drugs are the taxanes which may provide additional 
benefit in the neoadjuvant setting. Taxanes disrupt microtubule function in the cells and 
thereby cell cycle progression is suppressed and apoptosis may be triggered44. In Japan, there 
is an ongoing three-armed trial, NExT, comparing neoadjuvant cisplatin- fluorouracil with or 
without the addition of radiotherapy and neoadjuvant cisplatin- fluorouracil -taxane in the 
treatment of squamous cell carcinoma in the oesophagus45.  The CROSS trial46, where 
surgery alone was compared with neoadjuvant weekly carboplatin and taxane concurrent with 
radiotherapy followed by surgery, has received much attention. In this trial the addition of 
chemoradiotherapy to surgery improved 5-year survival from 33 to 47%. These promising 
13 
 
results warrant further investigations to compare the effect with other neoadjuvant regimens. 
There are conflicting results from retrospective analyses comparing the CROSS-regimen with 
neoadjuvant cisplatin- fluorouracil47,48 and results from prospective trials are awaited. There 
are two ongoing trials, Neo-AEGIS and ESOPEC, comparing the CROSS regimen with the 
MAGIC regimen (peri-operative epirubicin, fluorouracil and cisplatin) or the FLOT-regimen 
(peri-operative fluorouracil, folinic acid, oxaliplatin and docetaxel) in patients with 
adenocarcinoma in the oesophagus or oesophago-gastric junction. There is also an ongoing 
trial in France, PROTECT, comparing the CROSS regimen with neoadjuvant oxaliplatin, 
fluorouracil and folinic acid (FOLFOX) concurrent with radiotherapy in patients with 
resectable cancer in the oesophagus or oesophago-gastric junction.  
2.1.3 Radiotherapy 
Radiotherapy in combination with chemotherapy with46 or without surgery49 can cure 
oesophageal cancer. However, radiotherapy used as a single modality is not an option when 
there is a curative intent. In the landmark trial conducted in the 1980s, RTOG 85-01, patients 
with oesophageal cancer were randomised to receive 64 Gy of radiotherapy or 50 Gy of 
radiotherapy concurrent with cisplatin and fluorouracil. Five-year survival was 26% among 
those randomised to receive chemoradiotherapy whereas none of the 62 patients randomised 
to receive radiotherapy were alive after 3 years49.  
When there is a curative intent, radiotherapy is given in small fractions during a couple of 
weeks, so called fractionated radiotherapy. The mechanisms that determine the response of 
tumours and normal tissues to fractionated radiotherapy are often referred to as the 4 R´s of 
radiobiology: Repair of DNA damage, Redistribution of cells in the cell cycle, Repopulation, 
and Reoxygenation of hypoxic tumour areas: 
Repair of DNA: Radiotherapy 
generates highly reactive free 
radicals from water molecules, 
so called reactive oxygen species 
(ROS).  The ROS cause lethal 
and sublethal damage to the 
DNA. Malignant cells often 
have suppressed repair pathways 
preventing them from sufficient 
repair before the next dose of 
radiation is given during a 
course of fractionated 
radiotherapy50. Normal cells 
however will be able to repair 
the sublethal damage between 
radiotherapy doses. 
Chemotherapy may enhance the 
effect of radiotherapy through 
inhibition of the repair process of sublethal damage. 
Redistribution of cells in the cell cycle: Cells exhibit different radiosensitivity during 
different phases of the cell cycle which was shown already in 196851. The phases of the cell 
cycle are visualized in Figure 7.  
During the relatively brief period of the cell cycle when the chromosomes are separated, the 
mitotic phase (M-phase), the cells are most sensitive to DNA-damaging agents. In opposite, 
in the late S-phase when the replication of the DNA is finished the cells are most resistant to 
Figure 7 Phases of the cell cycle 
Source: Personal collection 
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radiation. Chemotherapeutic agents may enhance the effect of radiotherapy through 
redistributing cells to the more radiosensitive parts of the cell cycle.  
Repopulation: During the later phase of a radiotherapy course the tumour can speed up the 
regeneration of new tumour cells52.  This so called accelerated repopulation can be inhibited 
by cytotoxic agents.  
Reoxygenation: Solid tumours have smaller or larger volumes that are less well oxygenated 
than normal tissues. The resulting hypoxia may inhibit but it may also accelerate tumour 
progression. Inhibition is caused by cell-cycle arrest, apoptosis and necrosis of tumour cells. 
Accelerated progression may be promoted by hypoxia through evolution of mechanisms that 
enable tumour cells to overcome nutritive and oxygen deprivation53. Hypoxia also increases 
the resistance to radiotherapy and chemotherapy54. During the course of fractionated 
radiotherapy, the proportion of hypoxic cells remain constant which is a proof of hypoxic 
cells becoming reoxygenated55. This phenomenon where hypoxic cells become oxygenated 
during fractionated radiotherapy is called reoxygenation.  
The rationale behind giving 
fractionated radiotherapy is to allow 
the repair of normal tissues from 
sublethal damage and repopulation 
of normal cells between treatments. 
At the same time tumour cells are 
reoxygenated and redistributed into 
more radiosensitive parts of the cell 
cycle and the likelihood of tumour 
control increases. Tumour cells have 
less capacity to recover than normal 
cells, and the aim of radiotherapy is 
to deliver enough radiation to kill the 
tumour cells but not so much 
radiation that seriously damage 
normal tissues. This can be illustrated 
by a schematic dose-response curve 
as shown in Figure 8. In this example 
the probability of tumour control is 
90 % and the probability of normal 
tissue complications is 30% when the 
absorbed radiotherapy dose is 70 Gy. 
It has not been established what the optimal radiotherapy dose is in the preoperative setting 
for oesophageal cancer. In randomised studies comparing surgery alone and neoadjuvant 
chemoradiotherapy followed by surgery doses from 20 to 50.4 Gy have been used56. In a 
meta-analysis there seems to be a dose-response relationship57. However, the optimal 
radiotherapy dose depends on selection and dose of drugs given concurrent with radiotherapy 
as well as age and comorbidity of the patient. 
When delivering definitive chemoradiotherapy the gold standard is 50 Gy. In 2002, data from 
a randomised trial comparing high dose (64.8 Gy) to standard dose (50.4 Gy) concurrent with 
chemotherapy was published58. Dose escalation could not be proven to increase survival or 
loco-regional control. However, the radiotherapy techniques have evolved since then, and 
there are ongoing trials (for example the French Concorde trial, the Dutch Art-Deco trial and 
the British SCOPE 2 trial) addressing the question whether radiotherapy dose escalation will 
improve prognosis. 
Figure 8 Dose-response curve 
Curve A shows the probability of tumor control. 
Curve B shows the probability of normal tissue  
complications 
Source: Personal collection 
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Whether or not to include elective lymph nodes in the radiation field is a matter of 
controversy. Oesophageal cancer is well known for its tendency for early lymphatic spread 
and the idea is theoretically attractive. However, there is no strong evidence to support this 
view59. There are retrospective data suggesting that elective lymph node irradiation when 
given as definitive chemoradiotherapy60 or as a preoperative treatment61 reduces the risk of 
regional lymphatic recurrence or at least delays the recurrence but there is no gain in survival. 
Modern radiotherapy techniques such as Intensity Modulated Radiotherapy (IMRT) and 
Volumetric Modulated Arc Therapy (VMAT) will deliver more conformal treatment than 
previously used techniques. Consequently, previously incidentally irradiated lymph nodes 
will with the new techniques not be irradiated and recurrence patterns need to be followed 
carefully.  
2.1.4 Neoadjuvant treatment 
Several randomised controlled trials have compared different chemotherapy or 
chemoradiotherapy regimens combined with surgery versus surgery alone in patients with 
oesophageal cancer. Meta-analyses from the Australasian Gastro-Intestinal Trials Group and 
from the Cochrane library have shown a clear survival benefit for multimodality treatment to 
surgery alone56,62. The survival advantages were seen in both squamous cell carcinoma and 
adenocarcinoma, although it did not reach statistical significance in patients with squamous 
cell carcinoma treated with neoadjuvant chemotherapy. The treatment effect did not seem to 
be as large for neoadjuvant chemotherapy as for neoadjuvant chemoradiotherapy and an 
indirect comparison showed a trend towards survival benefits for neoadjuvant 
chemoradiotherapy compared to neoadjuvant chemotherapy. Direct comparisons provide a 
higher level of evidence than indirect comparisons, and prior to the publication of the NeoRes 
I trial there have been only two randomised clinical trials comparing the effect of neoadjuvant 
chemotherapy and neoadjuvant chemoradiotherapy in the treatment of oesophageal 
adenocarcinoma. Stahl et al. evaluated 119 patients with adenocarcinoma in the distal 
oesophagus or gastric-oesophageal junction (Siewert I-III) who had been randomly assigned 
to receive neoadjuvant treatment with 14.5 weeks of cisplatin, fluorouracil and leukovorin or 
12 weeks of cisplatin, fluorouracil and leukovorin followed by three weeks of cisplatin and 
etoposide given concurrently with radiotherapy (2 Gy x 15)63,64. Burmeister et al. randomised 
75 patients with adenocarcinoma in the oesophagus or gastric-oesophageal junction to receive 
neoadjuvant treatment with 6 weeks of cisplatin and fluorouracil with or without the addition 
of radiotherapy (3 Gy x 15)65. In both trials there were significantly better pathologic 
response rates among those who received radiotherapy in addition to chemotherapy. This was 
however not translated into better overall survival, although there was a trend towards better 
survival in favour of chemoradiotherapy in the trial conducted by Stahl et al. No 
corresponding comparative trials with modern surgical techniques have been completed in 
patients with squamous cell carcinoma. 
2.1.5 Targeted therapies 
With increasing insights into the molecular pathways of carcinogenesis, a variety of 
molecular targeted agents have been developed. These drugs interfere with signaling 
pathways that in various ways regulate cell growth and proliferation. Also in oesophageal 
cancer there are several pathways involved in the carcinogenesis that are potential targets for 
drugs. 
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The human epidermal 
growth factor receptor 
(EGFR) is a trans-
membrane protein. 
When activated it 
causes activation of 
intracellular pro-
oncogenic pathways. Several 
drugs have been developed to 
block the extracellular 
domain, such as the anti-
EGFR antibodies cetuximab 
and panitumumab. Other 
smaller drugs, tyrosine-kinase 
inhibitors such as gefitinib 
and erlotinib, have been 
developed to pass the cellular 
membrane and block the 
intracellular portion of the 
protein (Figure 9).  
High expression of the transmembrane 
protein EGFR has been shown to be a negative prognostic factor in patients with 
adenocarcinoma or squamous cell carcinoma in the oesophagus66,67.  When activated, EGFR 
causes activation of intracellular pro-oncogenic pathways. This is the rationale behind 
targeting the EGFR-pathway in the treatment of oesophageal cancer. 
In 2008 data were published showing promising results for cetuximab in addition to 
chemoradiotherapy in the treatment of patients with oesophageal cancer68. A few years later, 
in 2013, Crosby et al. published discouraging results from a randomised trial where cisplatin, 
capecitabine and radiotherapy were given with or without cetuximab. They found that 
treatment intensity was decreased in patients receiving cetuximab compared to those only 
receiving chemoradiotherapy. In the long-term follow-up, there was no significant difference 
in overall survival between those allocated to receive cetuximab and those allocated to 
chemoradiotherapy alone, but survival was decreased in patients who received lower doses of 
chemotherapy and radiotherapy69,70. Soon after the initial report from Crosby and co-workers,  
Suntharalingam et al. presented data showing that when adding cetuximab to cisplatin, 
paclitaxel and radiotherapy overall survival did not increase71. Disappointingly, nor have any 
of the other drugs targeting the EGFR-receptor showed any benefits for patients with 
oesophageal cancer. 
Another transmembrane protein is the ErbB2, frequently called HER-2. When activated, 
downstream oncogenic pathways are triggered. Several drugs have been developed to target 
the pathway and the antibody trastuzumab directed against the extracellular domain has been 
proven to be efficient in metastatic HER-2 overexpressing adenocarcinomas arising from the 
gastro-oesophageal junction72. 
Vascular endothelial growth factor, VEGF, is a family of transmembrane proteins involved in 
angiogenesis which is essential for tumour growth. Ramucirumab, an antibody directed 
against the VEGF 2, has a modest activity in the treatment of advanced cancers deriving from 
the gastro-oesophageal junction73,74.   
Figure 9 Cellmembrane with transmembrane proteins.  
Blockage of the transmembrane proteins (eg EGFR) with 
an antibody or a tyrosine-kinase inhibitor will inhibit 
intracellular signals and thereby inhibit carcinogenesis. 
 
Source: Personal collection 
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2.2 SIDE EFFECTS 
One of the central tenets of medical ethics is to do no harm. This forms an ethical dilemma to 
surgeons and oncologists treating patients with oesophageal cancer as treatment with curative 
intent is highly toxic. When using evidence-based medicine physicians prescribe treatment 
that is more likely to benefit than to harm the patient. Still, in many types of cancer with high 
mortality rates such as oesophageal cancer, a number of patients are given toxic treatments 
they derive little benefit from. When assessing the risks versus benefits of different treatment 
options for a given patient, physicians need a thorough understanding of both the risks and 
the benefits of the available treatment options. The benefits of treatments are often well 
documented, however, toxicity data from treatment of oesophageal cancer are more scarcely 
reported, especially long-term toxicity75. 
2.2.1 Side effects from chemotherapy 
The toxicity of chemotherapy used in the treatment of oesophageal cancer is similar to the 
toxicity from treatment of other cancers. Chemotherapy causes more or less invariably some 
level of acute bone marrow depression. Depending on the severity of the depression this may 
result in serious infections, sometimes even life-threatening. More infrequently 
thrombocytopenia results in bleeding complications. Nausea and vomiting are common acute 
side effects of chemotherapy that in complicated cases and/or if not adequately treated may 
result in decreased treatment intensity. Some chemotherapeutic agents may cause acute 
allergic reactions. Depending on the choice of chemotherapy acute and long-term ototoxic, 
renal and neurotoxic effects are also seen.  
2.2.1.1 Cardiac side effects from chemotherapy 
Fluorouracil is one of the most widely investigated antineoplastic agents in respect of causing 
myocardial ischemia76. Silent ischemic changes have been found in as many as 68% of 
patients receiving continuous fluorouracil. Changes in the electrocardiogram (ECG) were 
more frequent among patients who had known coronary artery disease77. Cardiac arrhythmias 
has also been reported in conjunction with fluorouracil infusion78. Typically the cardiac side 
effects arise during the infusion, and stops after cessation of the treatment76. The mechanisms 
behind the cardiotoxic effects of fluorouracil are not fully understood, but vasospasm has 
been suggested to be a main contributor. Other potential contributors are endothelial 
dysfunction causing thrombosis and direct myocardial injury79. 
Cisplatin has also been implicated as a cause of arrhythmias and ischemic cardiac disease76, 
even though not as well investigated as fluorouracil. The mechanisms behind have been 
suggested to include vascular damage, dysfunction in the platelet aggregation and 
hypomagnesemia80. 
2.2.1.2 Pulmonary side effects from chemotherapy 
Pulmonary toxicity is a well-known side effect of some chemotherapeutic agents. In the acute 
setting interstitial pneumonitis characterized by progressive dyspnoea and sometimes fever 
might be observed. The most common late onset toxicity is pulmonary fibrosis manifesting 
itself by dyspnoea, non-productive cough and fever. One of the most well-known agents to 
cause pulmonary toxicity is bleomycin, a drug that has been used since the 1960s. However, 
agents commonly used in the treatment of oesophageal cancer rarely exert pulmonary toxic 
effects. Although, oxaliplatin81 and taxanes82 have both been described to cause interstitial 
pneumonitis. In a study of 86 patients with breast cancer or lymphoma treated with 
radiotherapy, with or without the addition of chemotherapy, an acute reduction of pulmonary 
function tests was seen after treatment. Chemotherapy was seen to aggravate the reduction 
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caused by radiotherapy83. In the long-term follow up, the additive effect of chemotherapy to 
radiotherapy was however abolished84. 
2.2.2 Side effects from radiotherapy 
When administering radiotherapy, 
nearby organs to the target will be 
incidentally irradiated as illustrated 
by the dose distribution in Figure 10. 
Therefore, common side effects from 
radiotherapy of the oesophagus are 
related to irradiation of the 
oesophagus, the heart and the lungs. 
The extent of side effects is related to 
the radiation dose and to the irradiated 
volume. 
2.2.2.1 Oesophageal side effects 
from radiotherapy 
Mucosal cells lining the oesophagus 
have a rapid turnover and acute side 
effects from the oesophagus are more 
or less invariably seen when treating 
oesophageal cancer with radiotherapy. 
Acute oesophagitis can, depending on 
individual radiosensitivity and radiation 
doses, be severe and cause grave dysphagia. Late oesophageal side effects from radiotherapy 
include strictures, chronic ulcers and fistulas. Patho-morphologically fibrosis is seen.85 
2.2.2.2 Cardiac side effects from radiotherapy 
Ever since the 1960s when radiotherapy of Hodgkin´s lymphoma had become more frequent 
it has been known that the heart might be damaged by radiotherapy. The risk increases with 
radiotherapy dose and other risk factors for cardiovascular disease86. Much of the knowledge 
of radiation-induced cardiac disease derives from studies of patients with Hodgkin´s 
lymphoma or breast cancer as these patients often are long-term survivors of cancer. Due to a 
relatively low incidence and low cure rates, data on cardiac morbidity after treatment for 
oesophageal cancer is scarce. However, better treatment strategies have resulted in better 
long-term outcome, and cardiac morbidity in patients treated for oesophageal cancer is 
therefore becoming a concern. 
Acute radiation-induced pericarditis usually appears within a few weeks after cessation of 
radiotherapy manifesting itself by fever, tachycardia and chest pain. It is usually self-limiting, 
but approximately 20% later develop chronic pericarditis87, which can be asymptomatic or it 
can be severe with risk of tamponade86. Chronic pericarditis may also develop without 
previous signs of acute pericarditis88 
Radiation also causes vascular damage. After irradiation there is an increased vascular 
permeability followed by inflammatory infiltrate. This results in collagen disposition and 
fibrosis eventually resulting in coronary artery disease which typically is clinically 
manifested 10-15 years after exposure as ischemic heart disease87. 
Figure 10 Example of radiation therapy dose 
distribution from treatment of oesophageal 
cancer. High dose is coloured red and low dose is 
blue. The heart and the lungs are just next to the 
oesophageal tumour. 
                              Source: Personal collection 
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Various disturbances in the conduction system have been described such as sick sinus 
syndrome, various degrees of atrio-ventricular blocks and ventricular arrhythmias88. 
The myocardial cells divide slowly and are relatively resistant to radiotherapy, but interstitial 
fibrosis may occur89 as a result of vascular leakage. This in turn may lead to systolic and 
diastolic dysfunction90. 
There is also an increased risk of valvular disease after thoracic irradiation although the 
latency period is very long. In a retrospective study of patients with Hodgkin´s lymphoma the 
median time to symptoms was 22 years91.  
2.2.2.3 Pulmonary side effects of radiotherapy 
Pulmonary side effects from radiotherapy after treatment of Hodgkin´s lymphoma, breast 
cancer and lung cancer are fairly well documented, but the effects on patients treated for 
oesophageal cancer are scarcely reported.  
Acute pulmonary reaction after radiotherapy, pneumonitis, is usually manifested within 1-3 
months after treatment with cough, dyspnoea and fever. The histopathologic findings are 
characterized by injury to small vessels and oedema92 which pathologists reported already in 
193993.  
Late pulmonary side effects after radiotherapy are characterized by fibrosis, which is a 
chronic pulmonary damage. Patients with acute pneumonitis may later develop fibrosis, but it 
may also develop without a previous history of pneumonitis. Patients with radiographic 
findings of fibrosis may have no symptoms from the lungs, or they may have varying degrees 
of dyspnoea which sometimes can be very disabling92. 
In patients treated for breast cancer or lymphoma with radiotherapy with or without the 
addition of chemotherapy, pulmonary function tests have been found to be decreased in the 
acute setting and in the long-term follow-up84,94,95 
The cardiopulmonary side effects caused by radiotherapy might be reduced when using 
newer radiotherapy techniques. There are data suggesting that the use of IMRT could reduce 
post-operative pulmonary complications after oesophageal resection by reducing mean-lung 
dose96. A recently published retrospective trial found a lower rate of cardiac mortality among 
patients with oesophageal cancer older than 65 years treated with IMRT than for those treated 
with 3D conformal radiotherapy97  which might suggest that sparing of the heart and/or lungs 
results in lower cardiac mortality.  However, with the use of IMRT, or the more recently 
developed technique VMAT, larger volumes of the lungs will receive low doses of radiation 
and the clinical effects of this remain to be established. 
2.2.3 Measurement of pulmonary function 
The most frequently used test of pulmonary function is the spirometry98 when exhaled 
volumes of air are measured. Such volumes are the vital capacity (VC), which is the 
maximum volume of air that can be exhaled after full inspiration, and the forced vital 
capacity in one second (FEV1), which is the maximum amount of air that can be exhaled 
during the first second after full inspiration. The measurement of the diffusion capacity of 
carbon monoxide (DLCO) gives information on the function of the alveolar membranes and 
is a more sensitive method to detect drug-induced pulmonary damage99. 
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3 AIMS 
The aims of this thesis are: 
To evaluate if the addition of neoadjuvant radiotherapy to neoadjuvant chemotherapy 
improves outcome in patients with cancer in the oesophagus or cardia. 
To evaluate patterns of recurrence after multimodality treatment with curative intent of 
cancer in the oesophagus or cardia. 
To evaluate the effects on pulmonary function and cardiac exercise tests from multimodality 
treatment of cancer in the oesophagus or cardia.  
To evaluate the efficacy of cetuximab in addition to oxaliplatin, fluorouracil and radiotherapy 
in the treatment of patients with cancer in the oesophagus or cardia without distant metastasis. 
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4 MATERIALS AND METHODS 
4.1 THE NEORES I TRIAL 
Paper I, II and III are reports from the NeoRes I (Neoadjuvant therapy for Resectable 
Esophageal cancer) trial. The trial was conducted by the Scandinavian Esophageal and 
Gastric Cancer Group, SEGCG, enrolling patients in Sweden and Norway between 2006-
2013. Registration number in ClinicalTrials.gov: NCT01362127. No commercial support was 
given to this study. 
4.1.1 Eligibility criteria 
Patients with histologically proven adenocarcinoma or squamous cell carcinoma of the 
oesophagus or oesophagogastric junction with the clinical stages T1N1 or T2-3N0-1 and M0-
M1a according to the American Joint Committee on Cancer tumour-nodes-metastasis staging 
system 6th edition were eligible for inclusion. Patients with cervical cancer were required to 
be resectable without laryngectomy. Eligible patients were ≤ 75 years, had an Eastern 
Cooperative Oncology Group performance status of 0 to 1, were free from uncontrolled 
cardiac disease without a myocardial infarction within 12 months, had no complications from 
diabetes and no concurrent malignancy within the last five years. All had haematological and 
renal function within normal limits. A CT of the thorax and abdomen within one month from 
randomisation was required. Pre-treatment PET and endoscopic ultrasound were optional.  
In paper III patients randomised in Trondheim and Stockholm were included in the analysis. 
4.1.2 Chemotherapy 
All patients were scheduled for three 3-weekly cycles of cisplatin 100 mg/m2 day 1 and 
fluorouracil 750 mg/m2/24 hours, days 1-5. In case of hearing impairment, tinnitus or renal 
dysfunction cisplatin was replaced by carboplatin (AUC 5) in patients with squamous cell 
carcinoma or oxaliplatin 130 mg/m2 in patients with adenocarcinoma. Dose adaptations in 
case of haematological toxicity were predefined in the study protocol. In case of leukocyte 
count below 2.5 x109/l or thrombocyte count below 75x109/l chemotherapy had to be 
delayed.  
4.1.3 Radiotherapy 
Patients randomised to receive chemoradiotherapy were planned to receive 40 Gy 
concomitant with chemotherapy cycle 2 and 3 (2 Gy once daily in 20 fractions, 5 days a 
week) with a photon beam linear accelerator. A three-dimensional dose planning system was 
used. For tumours located mainly above the carina, the caudal border of the clinical target 
volume (CTV) was 5 cm below the tumour and the supraclavicular nodes defined the upper 
border. For tumours located mainly below the carina, the cranial border of the CTV was 5 cm 
cranial of the tumour and the lower border was defined by the celiac lymph nodes. In the 
lateral, anterior, and posterior directions, the CTV should embrace the gross tumour volume 
and paraoesophageal area with a margin of 1 cm, but also respecting anatomical barriers such 
as pleura, pericardium, and bone. The planning target volume was according to local routines. 
The dose to the lungs exceeding 20 Gy was kept as low as possible and was not to exceed one 
third of the lung volume. The volume of the heart that received >30 Gy was kept to a 
minimum. The dose to both kidneys was not to exceed 12 Gy, and the dose to one kidney was 
not to exceed 20 Gy. Maximum dose to the spinal cord was 40 Gy. 
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4.1.4 Surgery 
Surgery was scheduled 4-6 weeks after completion of the neoadjuvant treatment. The 
recommended operation for cancers in the cardia and in the distal third of the oesophagus was 
a thoracoabdominal Ivor-Lewis resection with an intrathoracic anastomosis, whereas a three-
stage-resection was recommended for cancers in the middle and upper part of the 
oesophagus. Two field lymphadenectomy was strived for. If the individual surgeon 
considered it appropriate other procedures were accepted, such as transhiatal 
oesophagectomy with laparotomy and cervical incision for distal or junctional cancers, or 
total gastrectomy for junctional tumours classified as Siewert II. 
4.1.5 Assessments during treatment 
Patients were reviewed every third week before administration of chemotherapy. During 
treatment with radiotherapy patients were assessed once weekly. Symptoms were assessed 
with the US National Cancer Institute´s Common Terminology Criteria for Adverse Events 
(CTCAE) version 3.0. 
4.1.6 Follow-up 
Follow up visits with clinical assessment were planned every third months during the first 
two years, and then every sixth months until five years after the end of treatment. 
Radiographic evaluation and endoscopy were performed on suspicion of recurrent disease. 
4.1.7 Histopathological evaluation 
All surgical specimens were analysed at Karolinska University Hospital in Stockholm by a 
single pathologist who was blinded to given treatment. Tumour response was classified 
according to Chireac et al.25 as described in section 1.5. Radical resection was defined as the 
absence of tumour cells within one mm of any resection margin100. 
4.1.8 Spirometry and cardiac stress tests 
Patients were scheduled to perform a spirometry and a cardiac stress test before and after 
oncological treatment. The investigations after oncological treatment were in most cases 
carried out 1 to 2 weeks before surgery. According to local routines in Stockholm, a 
spirometry and a cardiac stress test were done one to two years later, provided the cancer had 
not recurred. The timespan for the follow-up investigations was wide because of patients’ 
requests and surgical complications. 
Cardiac stress tests were performed on a stationary bicycle. Maximum exercise capacity, 
peak heart rate, peak blood pressure, significant changes on the ST-segment, and significant 
arrhythmias were recorded. A significant change on the ST-segment was defined as an 
elevation or depression of more than 1 mm. Significant arrhythmias were defined as atrial 
fibrillation or frequent ventricular extra beats. Maximum exercise capacity was achieved 
when the patient reached the subjective maximum exertion level, experienced chest pain, had 
changes in the electrocardiogram indicating ischemia, had severe arrhythmias or a pathologic 
blood pressure. In Trondheim, the resistance started at 50 W and was increased by 25 W 
every 2 minutes. In Stockholm, the resistance was determined individually based on the 
expected exercise capacity. 
Pulmonary function tests were performed with spirometries and carried out under 
standardized conditions in several different units. The best results of at least 2 consecutive 
investigations were recorded. Forced expiratory volume in 1 second (FEV1) and vital 
capacity (VC) were measured and the ratio FEV1/VC (FEV%) was calculated.  
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4.1.9 Study design and statistics 
The NeoRes I trial is a prospective, randomised, multicentre phase II study. Randomisation 
was performed at the Regional Oncological Centre in Stockholm with a computerized 
software. At randomisation, patients were stratified on histology. The allocation sequence 
was concealed to all investigators. All patient data were centrally collected and stored at 
Karolinska University Hospital and in a web-based database accessible to investigators.  
Statistical analyses were performed using the IBM SPSS computer program, version 23 and 
24 and Stata software, version 13.1 and 14.0. 
4.1.9.1 Paper I and II 
The trial required randomisation of 172 eligible patients to have a statistical power to detect 
an improvement of 15 % in complete histological response in the primary tumour with the 
use of a two-sided test with 0.80 statistical power and a significance level of 0.05. To 
compensate for ineligibility, the target number was set to 180 patients. Progression-free 
survival, overall survival and recurrence patterns were evaluated as secondary endpoints. The 
time-to-event was estimated with the Kaplan Meier method with the log-rank test to ascertain 
significance. Progression-free survival was defined as the time from registration until 
progression or death from any cause. Overall survival was defined as the time from 
registration until death. Living patients were censored at 60 months after randomisation. Data 
were analysed according to an intention-to-treat principle. We used cox proportional hazard 
models for univariate and multivariate analysis of factors with potential prognostic relevance 
for survival. Binominal logistic regression was used to ascertain effects of baseline 
characteristics on patterns of recurrence. Associations between categorical variables were 
tested with Fischer´s exact test and Chi-square test for association. The differences were 
considered significant at the 5% level (p < 0.05). 
4.1.9.2 Paper III 
A cohort of patients included in the NeoRes I trial, all randomised in Stockholm or 
Trondheim, were included. Parameters measured after oncological treatment and one to two 
years later were compared with baseline parameters by using Wilcoxon signed-rank test. For 
these three time points, changes over time were analysed with Friedman 2-way analysis of 
variance by ranks test. Mann Whitney U tests were used for detecting the differences between 
the treatment groups (chemoradiotherapy versus chemotherapy). The possible correlations 
between parameters were investigated by using Spearman rank correlation test. A p-value 
< 0.05 was considered statistically significant. 
4.1.10 Ethical considerations 
The NeoRes I trial was approved by the Research Ethics Committees in Sweden (registration 
numbers 2006/738-32 and 2008-40332) and Norway (Helseregion Midt-Norge registration 
number 4.2008.416). All participating patients provided written informed consent.  
4.2 THE LERFOX-C TRIAL 
Paper IV is the report from the LERFOX-C trial conducted by the Scandinavian Esophageal 
and Gastric Cancer group, SEGC. Patients were enrolled in Sweden, Denmark and Norway 
between 2011 and 2014. Registration number in ClinicalTrials.gov is NCT02636088 and 
EudraCT Number (EU clinical trials register) is 2008-006802-40. Merck Serono contributed 
with an unrestricted grant and has not been involved in study design, analysis and 
interpretation of results or writing of the report. 
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4.2.1 Eligibility criteria 
Patients had to be 18-75 years old, have a WHO performance status of 0-2, have an untreated 
histologically proven adenocarcinoma or squamous cell carcinoma of the oesophagus or 
oesophagogastric junction (type I and II according to Siewert´s classification101) with the 
clinical stages T2-T4, N0-N3, M0 according to the American Joint Committee on Cancer 
tumour-nodes-metastasis staging system 7th edition. Patients had non-resectable tumours or 
were considered non-operable for medical reasons. A CT of the thorax and abdomen was 
required, an endoscopic ultrasound of the oesophagus was recommended and an FDG-PET 
was optional. Further eligibility criteria were normal bone marrow, liver and renal function 
tests. Exclusion criteria included serious concomitant disorders and previous malignancy 
during the last two years before inclusion. 
4.2.2 Chemotherapy 
Patients were scheduled for three 3-weekly cycles of fluorouracil 750 mg/m2/24 hours, days 
1-5 and oxaliplatin day 1. Oxaliplatin was given with 130 mg/m2 in the first cycle. In cycle 2 
and 3, that was administered concomitant with radiotherapy, the dose was reduced to 85 
mg/m2. Dose adaptations in case of toxicity were predefined in the study protocol. If the 
patient experienced gastro-intestinal toxicity, the next chemotherapy cycle was delayed until 
recovery and in case of CTCAE grade III-IV fluorouracil was reduced by 20% in the 
following chemotherapy cycles. If the neutrophil count did not recover above 1.0 x 109/l 
before the next chemotherapy cycle was to be given, chemotherapy was to be delayed and 
granulocyte-colony stimulating factors (G-CSF) was to be given after the following 
chemotherapy cycle. Dose escalation was not permitted. 
4.2.3 Radiotherapy 
Concomitant with chemotherapy 50 Gy was given (2 Gy once daily in 25 fractions, 5 days a 
week) with a photon beam linear accelerator. A three-dimensional dose planning system was 
used. The boost clinical target volume (CTV)50Gy was to embrace in the lateral, anterior and 
posterior directions the gross tumour volume (GTV) with a margin of 1 cm, although 
respecting anatomical barriers such as pleura, pericardium and bone. Cranially and caudally a 
margin of 20 mm to GTV was recommended. For tumours located mainly above the carina 
the caudal border of the CTV46 Gy was recommended to include additional 3 cm caudally of 
CTV50 Gy and the supraclavicular nodes defined the upper border. For tumours located mainly 
below the carina, the cranial border of the CTV46 Gy was 3 cm cranial of the CTV50 Gy and the 
lower border was defined by the coeliac lymph nodes. The planning target volume was 
according to local routines. Maximum tolerated dose to the spinal canal was 45 Gy, dose to 
the lungs were not to exceed 20 Gy to 30 % of the volume, dose to the heart were not to 
exceed 40 Gy to 50% of the volume and dose to the kidneys were not to exceed 17 Gy to 
50% of the volume. 
4.2.4 Cetuximab 
A loading dose of 400 mg/m2 was given one week before the start of radiotherapy, and 
thereafter 250 mg/m2 was given weekly during the course of radiotherapy. To prevent allergic 
reactions an antihistamine and betametasone was to be given sixty minutes before infusion. 
Cetuximab was given at least one hour before infusion of oxaliplatin and radiotherapy. Dose 
adaptations in case of toxicity were predefined in the study protocol. In the case of 
hypersensitivity grade I or II according to CTCAE, infusion time was to be delayed. If grade 
III or IV occurred, further cetuximab was not to be given. Administration of systemic anti-
neoplastic drugs other than oxaliplatin, fluorouracil and cetuximab resulted in the patient´s 
removal from the trial. 
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4.2.5 Assessments during treatment 
Patients were reviewed before start of the second chemotherapy cycle and then once weekly 
during radiotherapy. Symptoms were assessed with the US National Cancer Institute´s 
Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. 
4.2.6 Follow-up 
Follow up visit with a clinical assessment and a CT-scan were planned four weeks after the 
end of treatment, and then every sixth months until 36 months after registration. An optional 
FDG-PET was planned after 12 months. 
4.2.7 Study design and statistical analysis 
LERFOX-C is a prospective, non-randomised, multicentre phase II study. All patient data 
were centrally collected and stored in a locked room and in a database accessible to a data-
manager at Karolinska University Hospital. The treatment was to be considered promising if 
the loco-regional control rate at one year was at least 50% but not of further interest if the 
loco-regional control rate at one year was 50% or less. With the use of a two-sided test with 
0.80 statistical power and a significance level of 0.05 the trial needed 85 eligible patients. To 
compensate for withdrawals, the target number was set to 90 patients. With the acquired 51 
patients, the power of the trial is 0.58. The time-to-event was estimated with the Kaplan-
Meier method. Loco-regional control rate was defined as the time from registration until 
loco-regional progression. Patients were censored at the last follow-up or at the date of death 
if they did not have any evidence of loco-regional failure. Progression-free survival was 
defined as the time from registration until progression or death from any cause. Overall 
survival was defined as the time from registration until death. Living patients were censored 
at the last follow up, approximately 36 months after registration. We used cox proportional 
hazard models for univariate and multivariate analysis of factors. Associations between 
categorical variables were tested with Fischer´s exact test and Chi-square test for association. 
The differences were considered significant at the 5% level (p < 0.05). Data were analysed 
with IBM SPSS Statistics for Windows, version 24.0 and Stata software, version 14.0. 
4.2.8 Ethical considerations 
The study was approved by the Research Ethics Committees Sweden (registration numbers 
2010/414 and 2014/1978-32), Denmark (registration number H-1-2011-002) and Norway 
(registration number 2012/1382). All participating patients provided written informed 
consent. 
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5 RESULTS 
5.1 PAPER I AND II 
5.1.1 Enrolment and given treatment 
Out of the 285 patients who were assessed for eligibility, 181 were randomised as displayed 
in Figure 11. Patients were recruited in nine cities in Sweden and Norway as detailed in Table 
1. Baseline characteristics were well balanced between the treatment groups as displayed in 
Table 2. 
Figure 11 Flow chart of the NeoRes I trial 
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Table 1 Patients included in Paper I and II by recruiting centre. 
Site Number of patients 
Stockholm (Radiumhemmet 
and Södersjukhuset) 
77 
Oslo (Ullevål and 
Radiumhospitalet) 
32 
Trondheim 24 
Bergen 16 
Umeå 15 
Örebro 6 
Eskilstuna 4 
Göteborg 4 
Karlstad  3 
 
Table 2 Demographic and disease-specific characteristics 
of patients enrolled in Paper I and II 
 
 Patients assigned to 
receive 
chemoradiotherapy 
Patients assigned to 
receive 
chemotherapy 
Median age (range) 63 (37-75) 63 (38-75) 
Sex   
Male 72 77 
Female 18 14 
ECOG Performance 
status 
  
0 75 77 
1 15 14 
Histology   
Adenocarcinoma 65 66 
Squamous cell carcinoma 25 25 
Tumour location   
Proximal 2 2 
Mid 13 13 
Distal 60 59 
Gastro-oesophageal 
junction 
15 17 
Clinical T-stagea   
1 1 1 
2 31 31 
3 58 59 
Clinical N-stagea   
0 33 34 
1 57 57 
 
aAmerican Joint Committee on Cancer tumour-nodes-metastasis staging system 6th edition 
Abbreviation: ECOG = Eastern Cooperative Oncology Group 
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Treatment intensity was good, 91% of the patients in both treatment groups received at least 
two of the planned three cycles of chemotherapy and 87% of those allocated to 
chemoradiotherapy received full dose radiotherapy. Tumour resection rate was high, 87% in 
the chemoradiotherapy group and 86% in the chemotherapy group. The majority of patients 
were operated on with a thoraco-abdominal approach (Ivor Lewis or three-stage 
oesophagectomy). Details are presented in Table 3. 
Table 3 Delivered treatment in Paper I and II 
Delivered treatment 
Patients assigned to 
receive 
chemoradiotherapy 
(n=90) 
Patients assigned to 
receive 
chemotherapy 
(n=91) 
p-
value 
Chemotherapy,  
3 cycles 
67 (74%) 78 (86%) 0.06c 
Full dose radiotherapy 78 (87%) 1 (1%)a  
Surgical approach 78 (87%) 78 (86%) 0.85c 
Ivor Lewis 
oesophagectomy 
49 (63%)b 54 (69%) b 0.51c 
Three-stage 
oesophagectomy 
19 (24%)b 16 (21%)b 0.55c 
Transhiatal 
oesophagectomy 
8 (10%)b 7 (9%)b 0.77c 
Total gastrectomy 2 (3%)b 1 (1%)b 0.62d 
No resection 12 (13%) 13 (14%) 0.85c 
 
Data are number of patients unless otherwise indicated 
aOne patient allocated to chemotherapy was accidently given 40 Gy 
bPercent of those resected 
 cChi-square test for association 
dFisher exact test 
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The number of serious adverse events did not differ between the treatment groups (p=0.14) as 
displayed in Table 4. 
Table 4 Serious adverse events in Paper I and II 
Serious adverse event 
Number of events 
among those 
assigned to receive 
chemoradiotherapy 
Number of events 
among those 
assigned to receive 
chemotherapy 
Infection  5 5 
Nausea and vomiting 6 2 
Nutritional deficiency 13 13 
Gastrointestinal symptoms 5 1 
Cardiovascular event  14 7 
Renal failure 4 7 
Neutropenia/thrombocytopenia 5 2 
Other  3 3 
Death 2 1 
Total number of serious 
adverse events  
57 41 
 
Data are number of patients unless otherwise indicated 
 
A serious adverse event was defined as an event which 
-required intervention to prevent permanent impairment 
-required initial or prolonged hospitalization and did not include planned hospitalisation 
-was disabling 
-was life-threatening 
-resulted in death 
  
30 
 
5.1.2 Pathological evaluation 
Patients treated with chemoradiotherapy were more likely to respond with complete 
histopathological response, have a radical tumour resection and less likely to have lymph 
node-metastasis at resection than those treated with chemotherapy. Details are displayed in 
Table 5 
Table 5 Pathological evaluation of resected specimens in NeoRes I 
 
Patients assigned  
to receive 
chemoradiotherapy 
(n=78) 
Patients assigned 
to receive 
chemotherapy 
(n=78) 
p-value 
Tumour regression 
grade 
  <0.001 
Grade I: Histological 
complete response 
22 (28%) 7 (9%) 0.002 
Grade II: 1-10 % 
residual carcinoma 
19 (24%) 5 (6%)  
Grade III: 11-50% 
residual carcinoma 
14 (18%) 5 (6%)  
Grade IV: >50% 
residual carcinoma 
23 (29%) 61 (78%)  
Radical resection (R0) 58 (87%) 58 (74%) 0.042 
Tumour-free 
longitudinal margin 
77 (99%) 75 (96%) 0.31 
Tumour-free 
circumferential margin 
69 (88%) 60 (78%) 0.09 
Viable lymph node 
metastasis at surgery 
27 (35%) 48 (62%) 0.001 
 
Data are number of patients unless otherwise indicated 
A logistic regression was performed to ascertain the effects of treatment, age, performance 
status, sex, histology, clinical T- and N-stage on the likelihood to achieve complete 
histopathological response in the primary tumour. Patients with squamous cell carcinoma 
were 2.49 times more likely to respond with complete histopathological response than those 
with adenocarcinoma (p=0.049) and patients allocated to chemoradiotherapy were 3.92 times 
more likely to respond with complete histopathological response than those allocated to 
chemotherapy (p=0.005). We did not find any other baseline characteristics affecting the rate 
of histopathological response. 
5.1.3 Survival 
All patients were followed until death or at least 60 months after randomisation. In the 
survival analysis patients were censored at 60 months after randomisation. There was no 
difference in overall survival or progressions-free survival between those allocated to 
chemoradiotherapy and those allocated to chemotherapy as displayed in Figures 12 and 13. 
Median overall survival was 31.4 months (95% CI 20.9-60.0) in patients in the 
chemoradiotherapy group and 36.0 months (95% CI 22.4-59.6) in patients in the 
chemotherapy group. Overall survival at five years reached 42.2% (95% CI 31.9%-52.1%) in 
the chemoradiotherapy group and 39.6% (95% CI 29.5%-49.4%) in the chemotherapy group, 
p= 0.60. Progression-free survival at five years reached 38.9% (95% CI 28.9%-48.8%) in the 
chemoradiotherapy group and 33.0% (95% CI 23.6%-42.7%) in the chemotherapy group, p= 
0.82.  
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Median overall survival was 30.8 months (95% CI 20.6-52.3) in patients with 
adenocarcinoma and 60.0 months (95% CI 23.7-60.0) in patients with squamous cell 
carcinoma, p=0.48. 
Median progression-free survival was 19.5 months (95% CI 13.6-33.7) in patients with 
adenocarcinoma and 49.4% months (95% CI 20.9-60.0) in patients with squamous cell 
carcinoma, p=0.17. 
 
Figure 12 Overall survival by treatment group in the NeoRes I trial. Intention to treat. 
 
 
 
Figure 13 Progression-free survival by treatment group in the NeoRes I trial.  
Intention to treat. 
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In the chemotherapy group 72 patients underwent tumour resection after at least two cycles of 
chemotherapy and no radiotherapy. In the chemoradiotherapy group 69 patients underwent 
tumour resection after at least two cycles of chemotherapy and at least 30 Gy. Among those, 
overall survival at five years was 47.8% (95% CI 35.7%-59.0%) in the chemoradiotherapy 
group compared to 44.4% (95% CI 32.8%-55.5%) in the chemotherapy group, p= 0.27. In 
this group of patients, referred to as the per protocol group, neither patients with 
adenocarcinoma nor patients with squamous cell carcinoma benefited from the addition of 
radiotherapy as displayed in Figure 14. 
 
Figure 14 Overall survival by treatment group and histology in the NeoRes I trial.  
Per protocol. 
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Patients with complete histological response reached a five-year survival rate of 75.9 (95% 
CI 55.9%-87.7%) compared to 40.5% (95% CI 31.9%-48.9%) in those who did not achieve 
complete histological response, p< 0.001 as displayed in Figure 15.  
Figure 15 Overall survival by tumour response
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5.1.3.1 Impact of risk factors on overall survival 
Baseline characteristics that could affect survival are listed in Table 6 which shows that 
female sex, lower clinical T-stage and squamous cell carcinoma tended to have a more 
favourable prognosis compared to male sex, higher clinical T-stage and adenocarcinoma.  
Table 6 The association between pre-treatment characteristics and overall survival 
 
Number 
of 
patients 
Univariate analysis Multivariate analysis 
Crude hazard 
ratio (95% CI)a 
p-value 
Adjusted hazard 
ratio (95% CI)b 
p-value 
Age      
<60 66 1.00  1.00  
>60 115 1.06 (0.71-1.58) 0.78 1.03 (0.68-1.54) 0.90 
Sex      
Male 149 1.00  1.00  
Female 32 0.56 (0.32-0.98)  0.04 0.57 (0.33-1.01) 0.05 
ECOG 
Performance 
Status 
     
0 152 1.00  1.00  
1 29 0.71 (0.41-1.25) 0.24 0.66 (0.37-1.17) 0.16 
Tumour location      
Cardia/distal 151 1.00  1.00  
Proximal/middle 30 1.05 (0.64-1.73) 0.84 1.39 (0.78-2.45) 0.26 
Histology      
Squamous cell 
carcinoma 
50 1.00  1.00  
Adenocarcinoma 131 1.40 (0.89-2.21) 0.15 1.69 (0.98-2.89) 0.06 
Clinical T-stage      
1-2 64 1.00  1.00  
3 117 1.47 (0.97-2.23) 0.07 1.60 (1.01-2.54)  0.05 
Clinical N-stage      
0 67 1.00  1.00  
1 114 1.20 (0.81-1.78) 0.37 1.16 (0.74-1.82) 0.52 
 
Abbreviation: CI; confidence interval. ECOG; Eastern Cooperative Oncology Group 
a Crude hazard ratios and 95% confidence intervals were obtained using univariate Cox proportional hazard 
regression models. 
b Adjusted hazard ratios and 95% confidence intervals were obtained using multivariate Cox proportional hazard 
regression models, adjusting for age, sex, performance status, tumour location, histology, clinical T- and N-
stage. 
 
As shown in Figure 16 none of the two treatment options seem to offer any advantage to a 
specific group of patients as specified by their different baseline characteristics.  
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Figure 16 Cox regression analysis with adjustment for baseline variables to assess if certain 
patient groups had an increased likelihood of improved survival with 
chemotherapy or chemoradiotherapy. 
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5.1.4 Patterns of recurrence 
All recurrences were diagnosed with a CT, histology or both. 
Potential prognostic factors predicting patterns of recurrence were analysed. We found no 
differences in frequency or patterns of recurrence between the treatment groups. Among 
patients who underwent tumour resection, 41 patients (53%) among those allocated to 
chemotherapy experienced a recurrence compared to 34 patients (44%) among those who 
were allocated to chemoradiotherapy (p=0.27). Potential prognostic factors predicting 
patterns of recurrence were analysed and no differences in frequency or patterns of recurrence 
between the treatment groups were seen. We found adenocarcinoma to be more prone to set 
early distant metastasis than squamous cell carcinoma. Details are in Table 7. 
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Table 7 Potential prognostic factors for primary site of recurrence for patients who 
underwent tumour resection 
 
Total 
number 
of 
patients 
(n=156) 
Locoregional recurrence 
with or without distant 
recurrence (n=38) 
Distant recurrence with or 
without locoregional 
recurrence (n=60) 
Number of 
patients (%) 
Odds ratio 
(95% CI) 
Number of 
patients (%) 
Odds ratio 
(95% CI) 
Age      
<60 59 18 (30.5%) 1.00 22 (37.2%) 1.00 
>60 97 20 (20.6%) 
0.55 
(0.26-1.19) 
38 (39.2%) 
1.07  
(0.52-2.19) 
Sex      
Male 126 32 (25.4%) 1.00 52 (41.2%) 1.00 
Female 30 6 (20.0%) 
0.75  
(0.29-2.14) 
8 (26.7%) 
0.50  
(0.20-1.28) 
ECOG  
Performance 
status 
     
0 132 35 (26.5%) 1.00 53 (40.2%) 1.00 
1 24 3 (12.5%) 
0.37  
(0.10-1.36) 
7 (29.2%) 
0.50  
(0.18-1.41) 
Histology      
Squamous 
cell 
carcinoma 
43 8 (18.6%) 1.00 11 (25.6%) 1.00 
Adeno-
carcinoma 
113 30 (28.3%) 
1.42  
(0.57-3.51) 
49 (43.3%) 
2.72  
(1.17-6.31)* 
Clinical  
T-stage 
     
1-2 56 15 (26.8%) 1.00 16 (28.6%) 1.00 
3 100 23 (23.0%) 
1.09  
(0.47-2.53) 
44 (44.0%) 
2.08  
(0.93-4.63) 
Clinical  
N-stage 
     
0 61  17 (27.9%) 1.00 19 (31.1%) 1.00 
1 95 21 (22.1%) 
0.79  
(0.35-1.80) 
41 (43.2%) 
1.77  
(0.82-3.85) 
Allocated 
treatment  
     
Chemo-
radiotherapy 
78 18 (23.1%) 1.00 26(33.3%) 1.00 
Chemo-
therapy 
78 20 (25.6%) 
1.05  
(0.50-2.22) 
34 (43.6%) 
1.59  
(0.80-3.17) 
 
Abbreviation: CI; confidence interval. 
Odds ratio and 95% confidence intervals were obtained using multivariate unconditional logistic regression 
models, adjusting for age, sex, performance status, histology, clinical T and N-stage and allocated treatment. 
* p <0.05. 
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5.1.5 Causes of death in the NeoRes I trial 
At the time of the final survival analysis 52 (58%) patients in the chemoradiotherapy group 
and 55 (60%) patients in the chemotherapy group had died. Among those allocated to 
chemoradiotherapy significantly more patients died from postoperative complications, of 
whom the last one died eight months after surgery. Details are specified in Table 8. 
Table 8 Cause of death 
Cause of death 
Patients assigned to 
receive 
chemoradiotherapy 
(n=90) 
Patients assigned to 
receive 
chemotherapy 
(n=91) 
p-value 
 
Oesophageal cancer 41 (46%) 47 (52%) 0.41a 
Other disease 2(2%) 6 (7%) 0.28b 
Post-operative 
complication 
8 (9%) 1 (1%) 0.02b 
Side effect from 
neoadjuvant 
treatment 
1 (1%) 1 (1%) 1.00b 
Total 52 (58%) 55 (60%) 0.72a 
 
Data are number of patients unless otherwise indicated 
aChi-square test for association 
bFisher exact test 
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5.2 PAPER III 
5.2.1 Enrolment and completed investigations 
All patients randomised in the NeoRes I trial in Trondheim and Stockholm, except four in 
whom none of the results from spirometries or cardiac exercise tests could be retrieved, were 
included in the analysis reported in Paper III. Baseline characteristics of included patients are 
displayed in Table 9. 
Table 9 Baseline characteristics of patients enrolled in Paper III 
 
 
Total Patients assigned 
to receive 
chemotherapy 
(n=53) 
Patients assigned to 
receive 
chemoradiotherapy 
(n=44) 
Median age (years)  63 64 
Sex    
Male 82 45 (85%) 37 (84%) 
Female 15 8 (15%) 7 (16%) 
WHO Performance 
Status 
   
0 88 47 (89%) 41 (93%) 
1 8 5 (9%) 3 (7%) 
unknown 1 1 (2%)  
Stage    
Stage II 30 16 (30%) 14 (32%) 
Stage III 66 36 (68%) 30 (68%) 
Stage IVa 1 1 (2%)  
Tumour location    
Proximal 1  1 (2%) 
Mid 19 10 (19%) 9 (20%) 
Distal 60 34 (64%) 26 (59%) 
Cardia type II 17 9 (17%) 8 (18%) 
Smoking    
Never smoked 13 5 (9%) 8 (18%) 
Stopped smoking more 
than one year ago 
25 15 (28%) 10 (23%) 
Smoker 44 26 (49%) 18 (41%) 
Unknown 15 7 (13%) 8 (18%) 
Diabetes mellitus    
Yes 18 9 (17%) 9 (20%) 
No 74 41 (77%) 33 (75%) 
Unknown 5 3 (6%) 2 (5%) 
Cardiovascular disease    
Yes 34 20 (38%) 14 (32%) 
No 59 30 (57%) 29 (66%) 
Unknown 4 3 (6%) 1 (3%) 
 
Data are number of patients unless otherwise indicated 
 
Of those assigned to chemotherapy, 77 % did the baseline spirometry and 68% did the 
baseline cardiac exercise test. The corresponding numbers for those assigned to 
chemoradiotherapy were 70% (baseline spirometry) and 84% (baseline cardiac exercise test). 
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In the chemotherapy group, 75% did the spirometry and 49% did the cardiac exercise test 
after oncological treatment. The corresponding numbers for the chemoradiotherapy group 
were 59% (spirometry) and 47% (cardiac exercise test). Of those assigned to chemotherapy 
32% of living patients who had not been diagnosed with progressive disease did the long-
term follow-up spirometry and 24% did the long-term follow-up cardiac exercise test. The 
corresponding numbers for those assigned to chemoradiotherapy were 45% (spirometry) and 
41% (cardiac exercise test). Details are in Figure 17. 
 
 
 
Figure 17 Trial profile Paper III 
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5.2.2 Treatment effects on pulmonary function 
There was a slight decrease in pulmonary function from baseline until after oncological 
treatment. A more pronounced decrease was seen from baseline until the long-term follow-up 
where median values decreased with 7.4% (FEV1) and 14% (VC). In the eight patients that 
completed all three investigations, a gradual decrease was seen in VC but not in FEV1. 
Details are in Tables 9 and 10. All patients in the analysis who did the long-term follow-up 
had been resected using a thoraco-abdominal approach. 
5.2.3 Treatment effects on cardiac exercise test 
Maximum exercise capacity and blood pressure decreased from baseline until after 
neodadjuvant treatment. Median values decreased with 17% (maximum exercise capacity) 
and 13% (maximum blood pressure). From baseline until the long-term follow up the median 
values for maximum exercise capacity decreased with 16% and the median values for 
maximum blood pressure decreased with 15%. Twelve patients completed all three cardiac 
exercise tests and among those we found no further deterioration in recorded values from 
after neoadjuvant treatment until the long-term follow-up. When the maximum exercise 
capacity was adjusted for haemoglobin levels (by dividing the maximum exercise capacity 
with current haemoglobin values) we found no decrease from baseline until after neoadjuvant 
treatment, but from baseline until the long-term follow up the median value was decreased 
with 18%. We did not find any changes in the occurrence of significant arrhythmias or 
changes in the ST-segment on the electrocardiogram from baseline until later. Details from 
the cardiac exercise tests are in Tables 9 and 10. All patients in the analysis who did the long-
term follow-up had been resected using a thoraco-abdominal approach. 
 
Table 9 Results from cardiac stress tests and spirometries, before and after neoadjuvant 
treatment 
 
 Before treatment 
Median 
(interquartile 
range) 
After neoadjuvant 
treatment  
Median (interquartile 
range) 
p-value 
(Wilcoxon 
signed  
rank test) 
Number 
of 
patients 
VC (l) 4.2 (3.5-4.8) 4.0 (3.0-4.8) 0.001 
51 FEV1(l) 2.9a (2.6-3.5) 2.9a (2.3-3.4) <0.001 
FEV% 73 (68-78) 73 (67-79) 0.609 
Max exercise 
capacity (W) 
150 (125-175) 125 (103-153) <0.001 
47 Hb (g/l) 139 (129-149) 118 (108-129) <0.001 
Max exercise 
capacity/hb (W/g/l) 
1.09 (0.93-1.33) 1.10 (0.93-1.33) 0.697 
Max heart rate (/min) 152 (142-164) 149 (139-164) 0.158 47 
Max blood pressure 
(mm Hg) 
200 (170-210) 175 (150-200) <0.001 42 
 
aMedian values are the same implicating that the reduction in pulmonary function is small. 
Abbreviations: VC; Vital Capacity, FEV1; Forced Expiratory Volume in 1 second 
  
42 
 
Table 10 Results from cardiac stress tests and spirometries, before the neoadjuvant treatment 
and 1-2 years later 
 
 
Before treatment 
Median 
(interquartile 
range) 
After 1-2 years 
Median 
(interquartile 
range) 
p-value 
(Wilcoxon 
signed  
rank test) 
Number 
of 
patients 
VC (l) 3.7 (3.3-4.8) 3.2 (2.6-4.2) 0.005 
11 
VC (% of ref.valuea) 96 (75-103) 74 (65-85) 0.004 
FEV1 (l) 2.7 (1.9-3.0) 2.49 (2.0-2.7) 0.013 
FEV1 (% of ref.valuea) 89 (64-95) 69 (57-87) 0.007 
FEV% 71 (55-74) 70 (60-87) 0.120 
Max exercise capacity 
(W) 
128 (115-170) 107 (80-125) 0.001 
15 
Max exercise 
capacity/hb (W/g/l) 
0.97 (0.88-1.14) 0.80 (0.64-0.92) 0.017 
Hb (g/l) 138 (132-149) 134 (128-139) 0.065 
Max heart rate (/min) 153 (142-166) 142 (129-157) 0.002 
Max blood pressure 
(mm Hg) 
200 (170-220) 170 (150-180) 0.012 
 
a reference values are adjusted by age, height and length 
Abbreviations: VC; Vital Capacity, FEV1; Forced Expiratory Volume in 1 second, Hb; hemoglobin 
5.2.4 Effects of radiotherapy on pulmonary function and cardiac stress test 
Radiotherapy doses to the lungs and heart for patients who received 40 Gy are listed in Table 
11. Due to a change in dose planning system in Stockholm, we did not retrieve doses to the 
lungs in nine patients and doses to the heart in seven patients.  
Table 11 Dosimetry data for patients who received 40 Gy 
 Median (interquartile range) Number of patients 
Overall treatment time (days) 29 (26-30) 38 
V20 lunga (%) 11.3 (8.1-16.2) 29 
Mean lung dose (Gy) 8.8 (6.5-11.8) 29 
V10 heartb (%) 80.0 (63.5-86.6) 31 
V30 heartc (%) 41.4 (21.2-71.7) 31 
 
aVolume of the lung receiving 20 Gy or more 
bVolume of the heart receiving 10 Gy or more 
cVolume of the heart receiving 30 Gy or more 
We did not find any correlation between doses to the heart and changes in maximum exercise 
capacity. Neither did we find any correlation between doses to the lungs and the recorded 
changes in pulmonary function.  
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In our material the addition of radiotherapy to neoadjuvant chemotherapy did not further 
aggravate the decline in pulmonary function and exercise capacity as demonstrated in Figure 
18. 
Figure 18 Maximum exercise capacity and vital capacity in patients receiving neoadjuvant 
chemotherapy or chemoradiotherapy
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5.3 PAPER IV 
5.3.1 Enrolment and delivered treatment 
Between 2011 and 2014 we assessed 124 patients for eligibility in Sweden, Denmark and 
Norway whereof 52 were included of whom one later withdrew consent. Thereafter the trial 
was prematurely stopped when results from two randomised clinical trials could not prove 
any benefit from the addition of cetuximab to chemoradiotherapy in the treatment of 
oesophageal cancer. During treatment three patients died and one developed metastatic 
disease after one course of chemotherapy. 41 patients (80%) received full dose radiotherapy, 
38 (75%) received all three courses of chemotherapy and 37 (73%) received at least four of 
the planned six doses of cetuximab. Median overall treatment time for the radiotherapy was 
35 days for those who received 50 Gy (range 33-40 days). There was no significant 
difference in treatment intensity between those selected for non-surgical treatment due to 
medical unfitness than for those with non-resectable tumours (p=0.40). The trial profile is 
displayed in Figure 19. 
Figure 19 Flow chart of the LERFOX-C trial 
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5.3.2  Adverse events 
There were no un-expected adverse events with possible, probable or certain relation to given 
treatment. Related adverse events grade III and IV reported once were hyponatremia, pain, 
fatigue, rash, tinnitus, anaemia, neutropenia, septicaemia, elevation of cardiac troponin T, 
hypotension, syncope and pneumonitis. Those reported more than once are displayed in Table 
12. Twenty-three patients (50%) experienced at least one related adverse event grade III and 
IV. 
Table 12 Related adverse events, grade III and IV during treatment, reported more than once 
in the 46 eligible patients. 
 
Adverse event Number of patients (%) 
Gastro-intestinal 16 (35) 
Dysphagia 7 (15) 
Anorexia 5 (11) 
Oesophagitis 4 (9) 
Mucositis 3 (7) 
Nausea 2 (4) 
Vomiting 2 (4) 
Infection 6 (13) 
Hypersensitivity 4 (9) 
Pain 2 (4) 
5.3.2.1 Fistulas 
Within six months from the end of treatment, six patients died from complications from 
fistulas between the oesophagus and airways (three patients) or aorta (three patients). Five of 
the patients had been selected for definitive chemoradiotherapy due to local extent of tumour, 
and one due to medical unfitness. None of them had known fistulas before treatment. Five 
had received 50 Gy, and one received 38 Gy. All six patients had received at least four doses 
of cetuximab. In two patients there were microscopic tumour in the fistula at the post-
mortem. In four of the patients post-mortems were not executed, but they had no clinical 
signs of tumour progression. Of those, two did a CT without radiographic signs of 
progression and one did an endoscopic examination without any macro- or microscopic 
findings of tumour. There was no significant association between pre-treatment dysphagia 
score or T-stage and fistula formation. 
5.3.3 Response to treatment 
Among the 46 patients eligible for response evaluation, three died and one had tumour 
progression during treatment. Of the 42 remaining patients 26 (62%) responded to 
chemoradiotherapy partially (36%) or completely (26%). Ten (24%) had stable disease. All 
patients with at least stable disease were evaluated with a CT-scan or magnetic resonance 
tomography (MRT) which was supplemented with an FDG-PET in four patients and 
histology in three patients. We did not find any significant differences in response rate 
between patients with adenocarcinoma and squamous cell carcinoma. Three patients (20%) 
of those with a partial response and five (45%) of those with a complete response did not 
have a tumour recurrence during the study. 
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5.3.4 Recurrence 
Four patients had disease progression and/or died during treatment. Of the remaining 42 
evaluable patients, 16 (38%) had their first occurrence of progression in a distant site, six 
(14%) of whom had a concurrent loco-regional relapse. Isolated loco-regional relapse as first 
site of recurrence was noted in 19 (45%) patients, one of whom was successfully treated with 
oesophageal resection.  
The probability of loco-regional control at one year was 47.3%, (95% CI 30.9% - 62.1%) as 
shown in Figure 20 
Figure 20 Loco-regional control in 46 evaluable patients 
 
Loco-regional control rate was better among those selected for definitive chemoradiotherapy 
because of cervical location of the tumour rather than local extent of the tumour.  It also 
seems as though they had better loco-regional control than those not operated on due to 
medical unfitness, even though significance levels did not reach below 0.05. Details are in 
Table 13. 
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Table 13 Baseline characteristics that might affect loco-regional control rate 
 Number 
of 
patients 
Univariate analysis Multivariate analysis 
HR (95% CI) p HR (95% CI) p 
Age      
<70 32 1 (reference)  1 (reference)  
>70 14 0.96 (0.40-2.30) 0.92 0.71 (0.26-1.95) 0.50 
ECOG 
Performance 
Status 
     
0-1 40 1 (reference) 0.93 1 (reference)  
2 6 1.05 (0.36-3.06)  0.94 (0.26-3.38) 0.92 
Body Mass Index      
<25 36 1 (reference)  1 (reference)  
>25 10 0.95 (0.38-2.36) 0.90 1.27 (0.37-4.30) 0.71 
Histology      
Adenocarcinomaa 9 1 (reference)  1 (reference)  
Squamous cell 
carcinomaa 
36 0.68 (0.28-1.64) 0.39 0.83 (0.26-1.95) 0.50 
Clinical T-stage      
2-3 21 1 (reference)  1 (reference)  
4 25 1.07 (0.49-2.32) 0.87 0.21 (0.03-1.26) 0.09 
Reason for no 
resection 
     
Cervical location 12 1 (reference)  1 (reference)  
Local extent of 
tumour 
23 3.15 (1.03–9.65) 0.05 14.05 (1.85–106.72) 0.01 
Medically unfit 11 3.48 (1.03-11.75) 0.05 3.81 (1.00–14.58) 0.05 
 
a One patient had adenosquamous carcinoma and is classified as missing. 
The multivariate cox-regression analysis included the following baseline characteristics: age, ECOG 
performance status, Body Mass Index, histology, clinical T-stage and reason for no resection 
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5.3.5 Survival 
The estimated overall survival at three years was 29.1% (95% CI 17.4-41.9%) for all 51 
patients included in the trial. One patient was lost to follow-up after 25 months. The 
remaining patients were followed until death or three years after registration. Median overall 
survival was 14.0 months (95% CI 7.8-21.78 months). The survival curve is presented in 
Figure 21. 
Figure 21 Intention-to-treat analysis of overall survival. 
 
 
Progression-free survival for the 46 patients that were not excluded from the analysis was at 
three years 14.7%, (95% CI 6.2%-26.6%). Median progression-free survival was 6.7 months 
(95% CI 5.4-12.1 months). 
In univariate and multivariate cox-regression analysis none of the covariates age, ECOG 
performance status, histology, T-stage or reason for non-resection were significantly 
associated with survival. 
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6 DISCUSSION 
6.1 METHODOLOGICAL CONSIDERATIONS 
6.1.1 Randomised and non-randomised clinical trials 
A randomised trial is a study where the patients are divided by chance into separate groups 
after which a control intervention is compared to an experimental intervention. When 
initiating the trial, it is not known which intervention is the best with regard to the endpoints 
of the trial. A well-conducted randomised clinical trial is today considered to provide the 
highest level of scientific evidence. NeoRes I (papers I, II and III) is a randomised trial. 
When new drugs are to be 
evaluated, clinical trials in 
different phases are conducted 
(Figure 22). LERFOX-C 
(paper IV) is a non-
randomised phase II trial 
where the aim was to evaluate 
if the new drug, cetuximab, 
had an acceptable toxicity 
profile and worked well 
enough to test in a larger 
randomised trial in this 
particular group of patients. 
But, results from randomised 
trials prompted early 
termination of LERFOX-C 
and the results from LERFOX-
C are to be regarded as confirmative. 
 
6.1.2 Validity 
Validity in a scientific investigation means that the trial is accurately measuring what it 
claims to be measuring. It can be divided into internal and external validity. 
6.1.2.1  Internal validity 
The internal validity of any type of study is to what extent it is measuring what it claims to be 
measuring within the source population. The source population is determined by the inclusion 
and exclusion criteria for the participants in the trial. The internal validity is to a large extent 
determined by to what degree systematic errors are minimized. Systematic errors can be sub-
divided into selection bias, information bias and confounding. 
6.1.2.1.1 Selection bias 
When conducting a trial, a selection of patients from a population is done. When there is a 
difference between the study-participants and the source population a selection bias is 
introduced. One of the best ways to avoid selection bias is to use random methods when 
selecting patients to intervention.  
Figure 22 
Phases of a clinical trial 
 
Phase I Test of an experimental treatment with the aim to 
find the correct dosage and to evaluate safety and 
side effects. 
Phase II Test of an experimental treatment with the aim to 
obtain preliminary data on effectiveness and 
continuing study of safety and side effects. A 
phase II-trial may be randomised or not. 
Phase III Test of an experimental treatment in regard to 
safety and effectiveness compared to a standard 
of care treatment. A phase III-trial is most often 
randomised. 
Phase IV These trials aim to study long-term benefits and 
side effects. They usually take place after the new 
treatment has been approved by the healthcare 
authorities. 
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The NeoRes I trial (papers I, II and III) is a randomised controlled trial and no other study 
design gives the power to balance unknown prognostic factors at baseline. A prerequisite is 
that the allocation sequence is hidden to the investigators which was secured in the NeoRes I 
trial as the allocation was computerized and performed by an independent institution. However, 
in paper III many of the patients did not perform the intended investigations which could 
introduce a selection bias, as it might be that caregivers found some patients to be too 
exhausted to undergo investigations or on the contrary too well to justify the investigations.  
The LERFOX-C trial (paper IV) is a non-randomised intervention trial where the risk of 
selection bias needs to be taken into account. In this trial an experimental drug is used in 
addition to conventional treatment. As physicians in general aim to tailor treatment for each 
individual patient there might be an unintended selection of patients in favour of patients that 
physicians believe the new treatment is best suited for. This effect is smaller when there are 
many participating centres and countries as in the LERFOX-C trial. 
6.1.2.1.2 Information bias 
When there are errors in the collection of data about study subjects it is called information 
bias or misclassification bias. Information bias can be further divided into non-differential 
and differential. 
Non-differential information bias is unrelated to the endpoints of the study. In large clinical 
trials, such as NeoRes I and LERFOX-C, it is quite probable that there have been a few 
typing errors when filling in the case-report forms, when transferring data from paper to 
database, when extracting data to the statistical software and finally to the manuscript. These 
errors are in general random and will not cause a false association between exposure and 
outcome, but if there are a large amounts of errors a true association might be hidden. As 
several physicians, nurses and data-managers have checked the data in these trials, the risk of 
a large volume of errors are minimized. 
Differential information bias is when the misclassification varies between the study groups so 
that the error differs between the groups, thus affecting an endpoint of the study differentially. 
This may cause false associations and is consequently seen as a very severe form of bias. For 
example, this could happen if the outcome is determined by subjective methods and the 
exposure is not blinded. There is some subjectiveness involved when differentiating between 
the histopathological grades II, III and IV in the NeoRes I trial. However, the examining 
pathologist was blinded to given treatment and the risk of differential bias was thereby 
eliminated.  
6.1.2.1.3 Confounding 
A confounder is a variable that is associated with both the exposure and the outcome resulting 
in an association of the wrong reason. Randomisation, as in the NeoRes I trial, is a powerful 
way to eliminate known and unknown confounding factors as it is likely that the groups will 
have similar distributions of confounders. Adjustment for known confounders can also be 
done with multivariate statistical models, as is the case in the NeoRes I and LERFOX-C 
trials. 
6.1.2.2 External validity 
External validity is the extent as to which results from a trial can be generalised to other 
populations that are sufficiently similar to the trial population.  
In the NeoRes trial only patients younger than 76 years with good performance status and no 
severe co-morbidity were included. Results might therefore not be readily extrapolated to 
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elderly patients or patients with a worse general condition. Patients included in the LERFOX-
C trial had a lower performance status than in the NeoRes I trial, but still there is an 
unneglectable amount of patients in the general oesophageal cancer population presenting 
with a worse performance status and results should be generalised with caution in aging 
patients and in patients with low performance status. 
6.1.3 Random errors and precision 
Random errors are in contrast to systematic errors unpredictable, and have no pattern. They 
can be reduced by increasing the sample size or repeating measurements and thereby 
precision is increased. The amount of random errors is estimated with confidence intervals 
and tested with p-values. 
The NeoRes I trial was designed for detecting a difference in histopathological response 
which was achieved, but it was underpowered for the survival analyses. However, as the 
survival differences between the two treatments were so small, a potential difference in a 
much larger study population would probably be very slight. In paper III a cohort of patients 
in the NeoRes I trial was included and only a limited number of patients completed a full 
investigational programme, partly due to the high recurrence rate among patients with 
oesophageal cancer. Consequently, the risk of type II errors (where true differences are not 
detected) cannot be neglected. This could be avoided with a larger study population. 
6.2 HISTOPATHOLOGICAL RESPONSE AND SURVIVAL 
The primary objective of the NeoRes I trial was to evaluate the rate of histopathological 
complete response after chemotherapy with or without the addition of radiotherapy. We 
found that the addition of radiotherapy improved response rate in the primary tumour, the 
radical resection rate increased and the number of metastatic lymph nodes at resection 
decreased. These findings confirm results from the two previously reported trials from 
Germany and Australia in patients with adenocarcinoma of the oesophagus63-65. The better 
response rate was however not translated into better survival for those treated with 
chemoradiotherapy, which is consistent with the results from the Australian trial. On the 
contrary, in the German trial a gain in survival was seen that almost reached significant 
levels. There are slightly different chemotherapy regimens and radiotherapy doses in the 
trials, but the German trial with the seemingly best effect from the addition of radiotherapy 
used the lowest radiotherapy doses. On the other hand, less extensive surgery was used in the 
German trial as only 48% of the patients who underwent tumour resection were operated on 
with a thoraco-abdominal approach compared to 83% in the NeoRes I trial and 100% in the 
Australian trial. Therefore, a possible explanation for the lack of survival benefit despite 
better tumour tissue response could be that the addition of radiotherapy may not increase 
local tumour control when extensive lymph node dissection is used. A support of this 
hypothesis is that there were fewer loco-regional recurrences among those who received 
radiotherapy in the German trial which was not seen in the NeoRes I and the Australian trial 
when more extensive surgery was practiced. As far as we know, no corresponding 
comparative trials have been completed in patients with squamous cell carcinoma.  
Nevertheless, complete histopathological response after neoadjuvant therapy is a well-
established prognostic factor for survival in oesophageal cancer25, which is also confirmed in 
the NeoRes I trial. It has previously been shown that there is a correlation between 
radiosensitivity and chemosensitivity in tumour tissue102-104. Consequently, a good 
pathological response in the primary tumour from chemotherapy is likely to become even 
better by the addition of radiotherapy, but with no survival benefit if followed by extensive 
surgery. However, a good tumour response at the primary site also indicates response on 
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peripheral micrometastases from chemotherapy and can partly explain why tumour response 
in the resected specimen is a prognostic marker for survival.  
When surgery is not preceded by neoadjuvant treatment, patients with squamous cell 
carcinoma have worse survival expectancy compared to patients with adenocarcinoma105. On 
the contrary, in NeoRes I patients with squamous cell carcinoma were more likely to respond 
with complete histopathological response and also showed a trend toward better survival 
compared to patients with adenocarcinoma. Our results are similar to the results presented 
from the CROSS-trial where patients were treated with neoadjuvant chemoradiotherapy 
followed by surgery29,46 suggesting that squamous cell carcinoma is more susceptible to 
current oncological treatment strategies than adenocarcinoma. These results could not be 
confirmed in the LERFOX-C trial as too few patients were included to evaluate survival 
differences between patients with different tumour histology. 
In LERFOX-C where cetuximab in addition to definitive chemoradiotherapy was evaluated, 
the estimated 3-year survival in this high-risk group of patients was as high as 31%. In other 
reports of treatment with definitive chemoradiotherapy 3-year survival ranges from 12.5% to 
45%49,106-109. As there are substantial differences in patient and tumour characteristics 
between the trials, comparison is to be made with caution. Survival in LERFOX-C compared 
to the NeoRes I trial was considerably worse, which to a large extent can be explained by 
higher tumour stage and worse general condition among included patients. Survival 
advantages from the addition of cetuximab to definitive chemoradiotherapy cannot be 
evaluated in a non-randomised trial such as the LERFOX-C trial other than in hypothesis-
generating discussions. However, during the time of inclusion results from two randomised 
clinical trials were presented which could not prove any gain in survival from the addition of 
cetuximab in this group of patients. 
6.3 SIDE EFFECTS 
Treatment of oesophageal cancer with curative intent is toxic. The aim is always to give 
treatment that is more likely to benefit than to harm the patient. To be able to properly assess 
the risk versus benefits, a thorough understanding of potential side effects from the various 
treatment options is required. 
In NeoRes I acute side effects were equally distributed between the treatment groups, 
although the reduction in maximum exercise capacity tended to be more pronounced after 
chemoradiotherapy than after chemotherapy and postoperative complications were more 
severe in the chemoradiotherapy group as shown in another publication from the group110. 
Also, when analysing causes of death, we found that patients treated with neoadjuvant 
chemoradiotherapy were more likely to die from postoperative complications. Similar results 
were reported from the German trial evaluating the addition of radiotherapy to neoadjuvant 
chemotherapy as hospital mortality was increased after chemoradiotherapy followed by 
surgery63. In a recent meta-analysis neoadjuvant chemoradiotherapy tended to increase 
postoperative mortality which was not seen after neoadjuvant chemotherapy, even though a 
direct comparison could not prove any difference between the two treatment options111. 
After neoadjuvant treatment we found that the maximum exercise capacity measured on a 
stationary bicycle was reduced and the reduction remained 1-2 years after the following 
tumour resection. Similar acute effects on exercise capacity after neoadjuvant 
chemoradiotherapy were reported by Liedman et al.112, but could not be demonstrated after 
less intense neoadjuvant treatment as reported by Tatematsu et al.113. There are several 
possible explanations to the decline in exercise capacity. First it can be explained by a 
decrease in haemoglobin. After adjustment for haemoglobin levels we were unable to 
confirm the reduction in exercise capacity when assessed after neoadjuvant treatment. 
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However, 1 to 2 years later, haemoglobin levels were back to pretreatment values and could 
not explain the decrease in exercise capacity. Second, it can be caused by fatigue which is a 
well-known side effect from anti-cancer treatment. Third, the large surgical trauma may 
contribute to the long-term reduction in exercise capacity. Fourth, cisplatin, fluorouracil and 
radiotherapy are all well-known to have the potential to cause cardio-toxic side effects as 
described in section 2:2. 
We also found pulmonary function to be reduced after neoadjuvant treatment. Before surgery 
the effects were small, and maybe not clinically significant. But, 1-2 years later after surgery 
the reduction was more pronounced. As is the case with exercise capacity, pulmonary 
function after oncological treatment for oesophageal cancer is not well-documented. In a 
previous report where 19 patients were treated with chemoradiotherapy with palliative or 
curative intent a reduction in pulmonary function was seen114. In another report, when using a 
less aggressive chemoradiotherapy regimen, no reduction in pulmonary function could be 
demonstrated115. Late effect on pulmonary function after multimodality treatment of 
oesophageal cancer has to our knowledge not previously been reported. But, surgery alone 
for oesophageal cancer116,117 and chemoradiotherapy for lymphoma and breast cancer84,118 
have been shown to cause a long-lasting decrease in pulmonary function. Possible 
explanations to the decrease in pulmonary function are radiotherapy as discussed in section 
2:2 and surgery, partly explained by the thoracotomy procedure116. To further enhance the 
complexity, there might be a co-variation between pulmonary function and exercise 
capacity119. 
We did not find any significant differences in maximum exercise capacity and pulmonary 
function between those who received neoadjuvant chemotherapy and those who received 
neoadjuvant chemoradiotherapy. Many patients did not undergo the investigations, and the 
lack of difference between the treatment groups might be explained by a type II error. 
In LERFOX-C most patients had large tumours invading nearby organs and a performance 
status 1-2, and still as many as 80% received full dose radiotherapy and 75% received all 
three planned cycles of chemotherapy indicating that treatment was well tolerated. However, 
the vulnerability of these patients is illustrated by the fact that two patients died from tumour 
related factors during treatment and within six months from the end of treatment, as many as 
six patients died from complications from fistulas between the oesophagus and adjacent 
organs. The incidence of fistulas in LERFOX-C seems to be similar as reported from other 
trials after chemoradiotherapy in similar groups of patients108,109,120. Fistulas may develop 
after chemoradiotherapy when the tumour is susceptible for treatment and becomes necrotic. 
But, fistulas can also be the natural progression of the disease and it is often difficult to 
distinguish between the two. Risk factors for the development of fistulas are not well 
documented, but symptoms from pre-treatment stenosis have been found to be associated 
with fistula formation120 and in a retrospective analysis low serum cholesterol has been 
shown to be associated with oesophago-aortic fistulas121. We did not find T4-disease or pre-
treatment stenosis measured as dysphagia score to be risk factors for fistula formation which 
could well be attributed to the small number of patients in our trial. From our data we cannot 
rule out that cetuximab contributed to the development of fistulas, but in the two randomised 
clinical trials evaluating the addition of cetuximab to chemoradiotherapy an increased 
incidence of fistulas was not reported70,71.  
During the time of inclusion in the NeoRes I trial and the LERFOX-C trial minimal invasive 
surgical techniques with endoscopic methods have been developed, less aggressive 
chemoradiotherapy regimens such as the CROSS regimen have been introduced and 
radiotherapy techniques such as VMAT have been developed where doses to the heart and 
lungs can be reduced. With this, side effects might be reduced in future patients. 
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6.4 RECURRENCE PATTERNS 
Among evaluable patients in the LERFOX-C trial that did not die or progress during 
treatment, 83% experienced a tumour recurrence during the time of follow up. The 
corresponding number in the NeoRes trial was 48%. The large majority of patients included 
in the LERFOX-C trial experienced a loco-regional recurrence which was not seen in the 
NeoRes I trial. This can be explained by a larger number of patients with T4 disease and a 
less aggressive local treatment in the LERFOX-C trial as most patients did not undergo 
oesophageal resection.  
The risk of loco-regional recurrence after definitive chemoradiotherapy is high, and data from 
LERFOX-C seem to be similar as those reported by Stahl et al.107. However, it seems as 
though patients selected for non-surgical treatment due to cervical location of the tumour 
rather than patient-related factors had a better loco-regional tumour control. Cervically 
located tumours in the oesophagus are preferably treated with non-surgical methods as it 
increases the chance of larynx preservation without decreasing the chance of survival122 As 
their general condition is not the main reason to abstain from surgery, they are more likely to 
tolerate chemoradiotherapy than patients selected for non-surgical treatment due to medical 
unfitness, and this could explain the differences in tumour control in the LERFOX-C trial. 
Also, it has previously been shown that patients selected for non-surgical treatment due to un-
resectable tumours are less likely to have a long-term benefit from treatment than those 
selected for non-surgical treatment due to patient-related factors108. Correspondingly, we 
found that patients selected for non-surgical treatment due to cervical location of the tumour 
had better prognosis than those with un-resectable tumours. However, the assessment of loco-
regional relapse is challenging. In LERFOX-C the evaluation was primarily done using a CT-
scan which is a draw-back of the trial as more accurate results could have been retrieved if a 
PET-scan and biopsies were done on all patients. 
In the NeoRes I trial, the differences in tumour biology between squamous cell carcinoma 
and adenocarcinoma are highlighted in the recurrence patterns as distant metastases were 
more common as first site of recurrence in patients with adenocarcinoma. In LERFOX-C the 
number of included patients were too small to evaluate such differences, but the same 
patterns of recurrence was found by Xi et al. in patients treated with definitive 
chemoradiotherapy123. 
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7 CONCLUSIONS 
The addition of radiotherapy to neoadjuvant chemotherapy in the treatment of oesophageal 
and junctional cancer increases the rate of complete histopathological response and radical 
resection and also decreases the number of metastatic lymph nodes in the resected specimen. 
However, despite better tumour response, there was no gain in survival. Consequently, results 
from the NeoRes I trial do not support unselected addition of radiotherapy to neoadjuvant 
chemotherapy as standard of care. 
The addition of radiotherapy to neoadjuvant chemotherapy does not affect frequency or 
patterns of recurrence. 
Multimodality treatment of resectable oesophageal cancer causes short-term and long-lasting 
impairment in pulmonary function and exercise capacity. 
Even in high-risk patients, oxaliplatin, fluorouracil and cetuximab given concurrent with 
radiotherapy was well tolerated and has a curative potential in localized oesophageal 
carcinoma. But, based on results from phase III trials the addition of cetuximab cannot be 
recommended as standard of care. 
There is a substantial risk of fistula formation after treatment with definitive 
chemoradiotherapy in patients with oesophageal cancer. 
8 FUTURE PERSPECTIVES 
The NeoRes I trial adds to the growing evidence that squamous cell carcinoma and 
adenocarcinoma of the oesophagus are two different disease entities and are likely to benefit 
from different treatment strategies. Squamous cell carcinoma seems to be more susceptible to 
oncological treatment than adenocarcinoma and it might be that patients with squamous cell 
carcinoma can be spared surgery provided that tumour response can be assessed in a reliable 
way. In our research network we are planning a randomised trial comparing surgical resection 
with surveillance and rescue surgery in patients with complete response after 
chemoradiotherapy 
Over the last 40 years, treatment with curative intent of oesophageal cancer have evolved 
tremendously with the evolution of chemotherapy, radiotherapy and better surgical 
techniques. Still survival is poor, which is also visualized by results from the trials in this 
thesis. Immunotherapy is a more recent way of targeting tumours, where the immune system 
is stimulated to produce an anti-tumour response. Quite likely there will be a role for 
immunotherapy also in the treatment of oesophageal cancer. Questions that need an answer 
are who will benefit from the treatment and in what way immunotherapy is to be combined 
with other therapeutic alternatives. There are numerous ongoing trials addressing these 
questions, and within our Scandinavian research network (SEGCG) an investigator-initiated 
trial, INEC, recently started. 
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9 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Bakgrund 
Cancer i matstrupen är i västvärlden en ovanlig sjukdom. I Sverige insjuknar ca 500 personer 
per år. Sjukdomen ger sällan besvär i tidiga stadier vilket gör att cancern oftast är långt 
gången när den upptäcks och prognosen är förhållandevis dålig. Behandling med botande 
syfte kan ges om cancern inte har spridit sig till andra organ i kroppen och kan ges på tre sätt: 
(1) cytostatika samtidigt med strålbehandling, (2) cytostatika med eller utan samtidig 
strålbehandling följt av kirurgi eller (3) enbart kirurgi. Behandling med botande syfte är 
krävande och ger sidoeffekter. Syften med denna avhandling är att utvärdera effekter och 
sidoeffekter av behandling som ges med botande syfte till patienter med cancer i matstrupen. 
 
Metodbeskrivning 
Tre av fyra delarbeten i avhandlingen baseras på en Skandinavisk studie, NeoRes I. 
Patienterna i denna studie lottades till att få behandling med cytostatika med eller utan tillägg 
av strålbehandling följt av kirurgiskt avlägsnande av tumören. 
 
Det fjärde delarbetet är en sammanställning av resultat från en annan Skandinavisk studie, 
LERFOX-C. Patienterna i denna studie hade cancer i matstrupen där kirurgi av olika skäl 
bedömdes olämpligt. Behandlingen bestod av cytostatika, strålbehandling och cetuximab (en 
antikropp). 
 
Resultat 
181 patienter inkluderades i NeoRes I. Studien visade att patienter som utöver cytostatika 
även fick strålbehandling före kirurgi hade färre cancerceller i den bortopererade matstrupen 
än de som fick enbart cytostatika före kirurgi. Den mer intensiva behandlingen gav ingen 
överlevnadsvinst. Fem år efter att behandlingen påbörjats levde cirka 40% av patienterna 
oavsett vilken behandling de hade fått. 
 
Drygt hälften av patienterna som var med i NeoRes I var med i en delstudie där vi fann att 
lungfunktionen försämrades något och arbetskapaciteten försämrades markant efter 
cytostatika och strålbehandling. På lång sikt, 1-2 år senare, när patienterna även gått igenom 
en operation försämrades lungfunktionen ytterligare, och arbetskapaciteten var fortfarande 
påtagligt nedsatt. 
 
I LERFOX-C deltog 51 patienter. De hade sämre allmäntillstånd och mer avancerade tumörer 
än i NeoRes I. Av dem vi hade möjlighet att undersöka hade 47% inte fått tillbaka cancern i 
matstrupen efter ett år. Efter tre år levde 29% av patienterna. 
 
Slutsatser 
Resultaten från NeoRes I stöder inte rutinmässigt tillägg av strålbehandling till cytostatika 
som ges före operation av matstrupscancer.  
 
På kort sikt försämrar cytostatika och strålbehandling lungfunktion och arbetskapacitet hos 
patienter med matstrupscancer. På lång sikt, efter att patienterna också opererats, är 
försämringen fortsatt märkbar. 
 
Resultaten från LERFOX-C bekräftar resultat från tidigare studier att cytostatika, 
strålbehandling och cetuximab kan bota patienter med matstrupscancer. Andra större studier 
har dock visat att tillägget av cetuximab inte förbättrar behandlingseffekten och kan därför 
inte rekommenderas. 
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